

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 May 2011 (05.05.2011)

(10) International Publication Number
WO 2011/051243 A1

PCT

(51) International Patent Classification:
A01N 43/78 (2006.01) *A01P 3/00* (2006.01)

(21) International Application Number:
PCT/EP2010/066096

(22) International Filing Date:
26 October 2010 (26.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09174510.9 29 October 2009 (29.10.2009) EP
61/256,019 29 October 2009 (29.10.2009) US

(71) Applicant (for all designated States except US): **BAYER CROPSCIENCE AG** [DE/DE]; Alfred-Nobel-Str. 50, 40789 Monheim (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CRISTAU, Pierre** [FR/FR]; 4 Rue Marietton, F-69009 Lyon (FR). **TSUCHIYA, Tomoki** [JP/DE]; Sonnenstrasse 64, 40227 Düsseldorf (DE). **WACHENDORFF-NEUMANN, Ulrike** [DE/DE]; Oberer Markweg 85, 56566 Neuwied (DE). **DAHMEN, Peter** [DE/DE]; Altebrückerstr. 63, 41470 Neuss (DE).

(74) Common Representative: **BAYER CROPSCIENCE AG**; Business Planning and Administration, Law and Patents, Patents and Licensing, Alfred-Nobel-Str. 50, Building 6100, 40789 Monheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: ACTIVE COMPOUND COMBINATIONS

(57) Abstract: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a thiazol-4-carbonic acid ester of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.



WO 2011/051243 A1

Active compound combinations

The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a thiazol-4-carbonic acid ester of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively
5 controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.

It is already known that certain piperidinyl-substituted thiazol-4-carbonic amides can be used as fungicides (see WO 07/014290, WO 08/091594, WO 09/132785).

- 10 In WO 04/058751 certain piperidinyl-substituted thiazol-4-carbonic acid esters and -thioesters are described to have medicinal use. They can be employed to control blood pressure.

In WO 05/003128 the use of piperidinyl-substituted thiazol-4-carbonic acid esters and -thioesters as microsomal triglyceride transfer protein inhibitors (MTP-inhibitors) is described. A use for fungicidal pathogens is not described.

- 15 Since the environmental and economic requirements imposed on modern-day crop protection compositions are continually increasing, with regard, for example, to the spectrum of action, toxicity, selectivity, application rate, formation of residues, and favourable preparation ability, and since, furthermore, there may be problems, for example, with resistances, a constant task is to develop new compositions, in particular fungicidal agents, which in some areas at least help to fulfil the abovementioned requirements.
20

The present invention provides active compound combinations/compositions which in some aspects at least achieve the stated objective.


- It has now been found, surprisingly, that the combinations according to the invention not only bring about the additive enhancement of the spectrum of action with respect to the phytopathogen to be controlled that
25 was in principle to be expected but achieves a synergistic effect which extends the range of action of the component (A) and of the component (B) in two ways. Firstly, the rates of application of the component (A) and of the component (B) are lowered whilst the action remains equally good. Secondly, the combination still achieves a high degree of phytopathogen control even where the two individual compounds have become totally ineffective in such a low application rate range. This allows, on the one hand, a substantial

broadening of the spectrum of phytopathogens that can be controlled and, on the other hand, increased safety in use.

In addition to the fungicidal synergistic activity, the active compound combinations according to the invention have further surprising properties which, in a wider sense, may also be called synergistic, such as, for example: broadening of the activity spectrum to other phytopathogens, for example to resistant strains of plant diseases; lower application rates of the active compounds; sufficient control of pests with the aid of the active compound combinations according to the invention even at application rates where the individual compounds show no or virtually no activity; advantageous behaviour during formulation or during use, for example during grinding, sieving, emulsifying, dissolving or dispensing; improved storage stability and light stability; advantageous residue formation; improved toxicological or ecotoxicological behaviour; improved properties of the plant, for example better growth, increased harvest yields, a better developed root system, a larger leaf area, greener leaves, stronger shoots, less seed required, lower phytotoxicity, mobilization of the defence system of the plant, good compatibility with plants. Thus, the use of the active compound combinations or compositions according to the invention contributes considerably to keeping young cereal stands healthy, which increases, for example, the winter survival of the cereal seed treated, and also safeguards quality and yield. Moreover, the active compound combinations according to the invention may contribute to enhanced systemic action. Even if the individual compounds of the combination have no sufficient systemic properties, the active compound combinations according to the invention may still have this property. In a similar manner, the active compound combinations according to the invention may result in higher persistency of the fungicidal action.

Accordingly, the present invention provides a combination comprising:

(A) at least one thiazol-4-carbonic acid ester of formula (I)



in which

25 R^1 represents CF_3 or CHF_2 ,


R^2 represents methyl or CHF_2 ,

- 3 -

R³ represents cyclohexyl, (1R/1S)-1,2,3,4-tetrahydronaphthalen-1-yl, (1S)-1,2,3,4-tetrahydronaphthalen-1-yl, (1R)-1,2,3,4-tetrahydronaphthalen-1-yl or 1-naphthyl,

or

R³ represents



5

R⁴ represents hydrogen, fluoro, chloro, bromo or iodo,

R⁵ represents hydrogen, fluoro, chloro, bromo, iodo or phenyl

or an agrochemically acceptable salt thereof,

and

10 (B) at least one further active compound selected from the following groups

- (1) inhibitors of the ergosterol synthesis,
- (2) inhibitors of the respiratory chain at complex I or II,
- (3) inhibitors of the respiratory chain at complex III,
- (4) inhibitors of the mitosis and cell division,
- 15 (5) compounds capable of having a multisite action,
- (6) compounds capable of inducing a host defense,
- (7) inhibitors of the amino acid and/or protein biosynthesis,
- (8) inhibitors of the ATP production,
- (9) inhibitors of the cell wall synthesis,
- 20 (10) inhibitors of the lipid and membrane synthesis,
- (11) inhibitors of the melanine biosynthesis,

- 4 -

- (12) inhibitors of the nucleic acid synthesis,
- (13) inhibitors of the signal transduction,
- (14) compounds capable of acting as uncoupler,
- (15) other fungicides.

5 Preference is given to combinations comprising at least one compound of the formula (I) selected from the group consisting of

- (I-1) cyclohexyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- (I-2) cyclohexyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- 10 (I-3) (1S/1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- (I-4) (1S/1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- 15 (I-5) (1S)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- (I-6) (1S)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- (I-7) (1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- 20 (I-8) (1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- (I-9) 1-naphthyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- 25 (I-10) 1-naphthyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate,

- (I-11) 2-bromobenzyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- (I-12) 2-bromobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- 5 (I-13) 2,6-difluorobenzyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- (I-14) 2,6-difluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- (I-15) 2-chloro-6-fluorobenzyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate,
- 10 (I-16) 2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate,

Preference is further given to combinations comprising an inhibitor of the ergosterol synthesis selected from the group consisting of [Group (1)]:

- 15 (1.1) aldimorph (1704-28-5), (1.2) azaconazole (60207-31-0), (1.3) bitertanol (55179-31-2), (1.4) bromuconazole (116255-48-2), (1.5) cyproconazole (113096-99-4), (1.6) diclobutrazole (75736-33-3), (1.7) difenoconazole (119446-68-3), (1.8) diniconazole (83657-24-3), (1.9) diniconazole-M (83657-18-5), (1.10) dodemorph (1593-77-7), (1.11) dodemorph acetate (31717-87-0), (1.12) epoxiconazole (106325-08-0), (1.13) etaconazole (60207-93-4), (1.14) fenarimol (60168-88-9), (1.15) fenbuconazole (114369-43-6), (1.16) fenhexamid (126833-17-8), (1.17) fenpropidin (67306-00-7), (1.18) fenpropimorph (67306-03-0), (1.19) fluquinconazole (136426-54-5), (1.20) flurprimidol (56425-91-3), (1.21) flusilazole (85509-19-9), (1.22) flutriafol (76674-21-0), (1.23) furconazole (112839-33-5), (1.24) furconazole-cis (112839-32-4), (1.25) hexaconazole (79983-71-4), (1.26) imazalil (60534-80-7), (1.27) imazalil sulfate (58594-72-2), (1.28) imibenconazole (86598-92-7), (1.29) ipconazole (125225-28-7), (1.30) metconazole (125116-23-6), (1.31) myclobutanil (88671-89-0), (1.32) naftifine (65472-88-0), (1.33) nuarimol (63284-71-9), (1.34) oxpoconazole (174212-12-5), (1.35) paclobutrazol (76738-62-0), (1.36) pefurazoate (101903-30-4), (1.37) penconazole (66246-88-6), (1.38) piperalin (3478-94-2), (1.39) prochloraz (67747-09-5), (1.40) propiconazole (60207-90-1), (1.41) prothioconazole (178928-70-6), (1.42) pyributicarb (88678-67-5), (1.43) pyrifenoxy (88283-41-4), (1.44) quinconazole (103970-75-8), (1.45) simeconazole (149508-90-7), (1.46) spiroxamine (118134-30-8), (1.47) tebuconazole (107534-96-3), (1.48) terbinafine (91161-71-6),
- 30

- (1.49) tetraconazole (112281-77-3), (1.50) triadimefon (43121-43-3), (1.51) triadimenol (89482-17-7), (1.52) tridemorph (81412-43-3), (1.53) triflumizole (68694-11-1), (1.54) triforine (26644-46-2), (1.55) triticonazole (131983-72-7), (1.56) uniconazole (83657-22-1), (1.57) viniconazole (77174-66-4), (1.58) 1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)cycloheptanol (129586-32-9), (1.59) methyl 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazole-5-carboxylate, (1.60) O-{1-[(4-methoxyphenoxy)methyl]-2,2-dimethylpropyl}-1H-imidazole-1-carbothioate (111226-71-2), (1.61) N-ethyl-N-methyl-N'-{2-methyl-5-(difluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}-imidoformamid, (1.62) N-ethyl-N-methyl-N'-{2-methyl-5-(trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}-imidoformamid, (1.63) voriconazole (137234-62-9) and (1.64) uniconazole-p (83657-17-4).
- 10 Particular preference is given to combinations comprising an inhibitor of the ergosterol synthesis selected from the group consisting of (1.3) bitertanol, (1.12) epoxiconazole, (1.16) fenhexamid, (1.17) fenpropidin, (1.18) fenpropimorph, (1.19) fluquinconazole, (1.30) metconazole, (1.41) prothioconazole, (1.46) spiroxamine, (1.47) tebuconazole, and (1.51) triadimenol

Preference is further given to combinations comprising an inhibitor of the respiratory chain at complex I or II selected from the group consisting of [Group (2)]:

- (2.1) diflumetorim (130339-07-0), (2.2) bixafen (581809-46-03), (2.3) boscalid (188425-85-6), (2.4) carboxin (5234-68-4), (2.5) fenfuram (24691-80-3), (2.6) fluopyram (658066-35-4), (2.7) flutolanil (66332-96-5), (2.8) furametpyr (123572-88-3), (2.9) furmecyclox (60568-05-0), (2.10) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) (88165-58-1), (2.11) isopyrazam (syn epimeric racemate 1RS,4SR,9RS), (2.12) isopyrazam (syn-epimeric enantiomer 1R,4S,9R), (2.13) isopyrazam (syn-epimeric enantiomer 1S,4R,9S), (2.14) isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), (2.15) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.16) isopyrazam (anti-epimeric enantiomer 1S,4R,9R), (2.17) mepronil (55814-41-0), (2.18) oxycarboxin (5259-88-1), (2.19) penflufen (494793-67-8), (2.20) penthiopyrad (183675-82-3), (2.21) sedaxane (874967-67-6), (2.22) thifluzamide (130000-40-7), (2.23) 1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (2.24) 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide, (2.25) 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide, (2.26) 1-methyl-3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2.27) N-(4'-chlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.28) N-(2',4'-dichlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.29) 3-(difluoromethyl)-1-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2.30) N-(2',5'-difluorobiphenyl-2-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (2.31) 3-(difluoromethyl)-1-methyl-N-(4'-prop-1-yn-1-yl)biphenyl-2-

yl)-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (2.32) 5-fluoro-1,3-dimethyl-N-(4'-prop-1-yn-1-ylbiphenyl-2-yl)-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (2.33) 2-chloro-N-(4'-prop-1-yn-1-ylbiphenyl-2-yl)nicotinamide (known from WO 2004/058723), (2.34) 3-(difluoromethyl)-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide
 5 (known from WO 2004/058723), (2.35) N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (2.36) N-[4'-(ethynylbiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (2.37) N-(4'-ethynylbiphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (2.38) 2-chloro-N-(4'-ethynylbiphenyl-2-yl)-nicotinamide (known from WO
 10 2004/058723), (2.39) 2-chloro-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-nicotinamide (known from WO 2004/058723), (2.40) 4-(difluoromethyl)-2-methyl-N-[4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]-1,3-thiazole-5-carboxamide (known from WO 2004/058723), (2.41) 5-fluoro-N-[4'-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (2.42) 2-chloro-N-[4'-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-nicotinamide (known from WO
 15 2004/058723), (2.43) 3-difluoromethyl-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (2.44) 5-fluoro-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (2.45) 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)-1H-pyrazole-4-carboxamide, (2.46) 2-chloro-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-nicotinamide (known
 20 from WO 2004/058723), (2.47) N-[1-(2,4-dichlorophenyl)-1-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (1092400-95-7) (WO 2008148570). and salts thereof.

Particular preference is given to combinations comprising an inhibitor of the respiratory chain at complex I or II selected from the group consisting of (2.2) bixafen, (2.3) boscalid, (2.4) Carboxin, (2.6) fluopyram, (2.10) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric
 25 racemate 1RS,4SR,9SR), (2.11) isopyrazam (syn epimeric racemate 1RS,4SR,9RS), (2.12) isopyrazam (syn-epimeric enantiomer 1R,4S,9R), (2.13) isopyrazam (syn-epimeric enantiomer 1S,4R,9S), (2.14) isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), (2.15) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.16) isopyrazam (anti-epimeric enantiomer 1S,4R,9R), (2.19) penflufen, (2.20) pen-thiopyrad, (2.21) Sedaxane, (2.26) 1-methyl-3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-
 30 1H-pyrazole-4-carboxamide.

Preference is further given to combinations comprising an inhibitor of the respiratory chain at complex III selected from the group consisting of [Group (3)]:

- (3.1) amisulbrom (348635-87-0), (3.2) azoxystrobin (131860-33-8), (3.3) cyazofamid (120116-88-3), (3.4) dimoxystrobin (141600-52-4), (3.5) enestroburin (238410-11-2), (3.6) famoxadone (131807-57-3), (3.7) fenamidone (161326-34-7), (3.8) fluoxastrobin (361377-29-9), (3.9) kresoxim-methyl (143390-89-0), (3.10) metominostrobin (133408-50-1), (3.11) orysastrobin (189892-69-1),
 5 (3.12) picoxystrobin (117428-22-5), (3.13) pyraclostrobin (175013-18-0), (3.14) pyrametostrobin (915410-70-7), (3.15) pyraoxystrobin (862588-11-2), (3.16) pyribencarb (799247-52-2), (3.17) trifloxystrobin (141517-21-7), (3.18) 5-methoxy-2-methyl-4-(2-{{[(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino]oxy}methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, (3.19) (2E)-2-(2-{{[6-(3-chloro-2-methyl-phenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl}-2-(methoxyimino)-N-
 10 methylethanamide, (3.20) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-pyridine-3-carboxamide (119899-14-8), (3.21) (2E)-2-(methoxyimino)-N-methyl-2-(2-{{[(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino]oxy}methyl}-phenyl)ethanamide, (3.22) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-(Formylamino)-2-hydroxy-benzamide (226551-21-9), (3.23) (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]ethoxy}imino)methyl]phenyl}ethanamide
 15 (326896-28-0), (3.24) (2E)-2-{2-[[{(2E,3E)-4-(2,6-dichlorophenyl)but-3-en-2-ylidene]amino}oxy]methyl}phenyl}-2-(methoxyimino)-N-methylethanamide (known from WO 02/12172), (3.25) (2E)-2-{2-[[{(1E)-1-(3-{{[(E)-1-fluoro-2-phenylvinyl]oxy}phenyl]ethylidene}amino}oxy]methyl}phenyl}-2-(methoxyimino)-N-methylacetamide, (3.26) methyl (2E)-2-{2-[(cyclopropyl[(4-methoxyphenyl)imino]methyl}thio)methyl}phenyl}-3-methoxyacrylate, (3.27) 2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (173662-97-0), , (3.28) (2R)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (394657-24-0) and salts thereof.

Particular preference is given to combinations comprising an inhibitor of the respiratory chain at complex III selected from the group consisting of (3.2) azoxystrobin, (3.3) cyazofamid, (3.4) dimoxystrobin, (3.7) fenamidone, (3.8) fluoxastrobin, (2.9) kresoxim-methyl, (3.10) metominostrobin,
 25 (3.12) picoxystrobin, (3.13) pyraclostrobin, (3.14) pyrametostrobin, (3.15) pyraoxystrobin, (3.17) trifloxystrobin, and salts thereof

Preference is further given to combinations comprising an inhibitor of the mitosis and cell division selected from the group consisting of [Group (4)]:

- 30 (4.1) benomyl (17804-35-2), (4.2) carbendazim (10605-21-7), (4.3) diethofencarb (87130-20-9), (4.4) ethaboxam (162650-77-3), (4.5) fuberidazole (3878-19-1), (4.6) pencycuron (66063-05-6), (4.7) thiabendazole (148-79-8), (4.8) thiophanate-methyl (23564-05-8), (4.9) zoxamide (156052-68-5) and (4.10) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyri-

midine (214706-53-3), (4.11) chlorfenazole (3574-96-7), (4.12) thiophanate (23564-06-9), and (4.13) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine (1002756-87-7).

Particular preference is given to combinations comprising an inhibitor of the mitosis and cell division selected from the group consisting of (4.2) carbendazim, (4.9) zoxamide and (4.10) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine.

Preference is further given to combinations comprising a compound capable of having a multisite action selected from the group consisting of [Group (5)]:

(5.1) bordeaux mixture (8011-63-0), (5.2) captafol (2425-06-1), (5.3) captan (133-06-2), (5.4) chlorothalonil (1897-45-6), (5.5) dichlofluanid (1085-98-9), (5.6) dithianon (3347-22-6), (5.7) dodine, (5.8) ferbam (14484-64-1), (5.9) folpet (133-07-3), (5.10) guazatine, (5.11) iminoctadine (13516-27-3), (5.12) iminoctadine triacetate (57520-17-9), (5.13) iminoctadine tris(albesilate) (169202-06-6), (5.14) copper oxide (1317-39-1), (5.15) copper oxychloride (1332-40-7), (5.16) copper hydroxide (20427-59-2), (5.17) copper sulfate (7758-98-7), (5.18) mancozeb (53988-93-5), (5.19) mancozeb, (5.20) maneb, (5.21) metiram, (5.22) oxine-copper (10380-28-6), (5.23) propineb (12071-83-9), (5.24) sulphur and sulphur preparations including calcium polysulphide, (5.25) thiram (137-26-8), (5.26) tolylfluanid (731-27-1), (5.27) zineb, (5.28) ziram (137-30-4), (5.29) copper naphthenate (1338-02-9), (5.30) dodine free base, (5.31) fluorofolpet (719-96-0), (5.32) guazatine acetate, (5.33) metiram zinc, (5.34) propamidine (104-32-5) and salts thereof.

Particular preference is given to combinations comprising a compound capable of having a multisite action selected from the group consisting of (5.4) chlorothalonil, (5.10) guazatine and (5.23) propineb.

Preference is further given to combinations comprising a compound capable of inducing a host defense selected from the group consisting of [Group (6)]:

(6.1) acibenzolar-S-methyl (135158-54-2), (6.2) probenazole (27605-76-1), (6.3) tiadinil (223580-51-6).

Preference is further given to combinations comprising an inhibitor of the amino acid and/or protein biosynthesis selected from the group consisting of [Group (7)]:

(7.1) andoprim (23951-85-1), (7.2) blasticidin-S (2079-00-7), (7.3) cyprodinyl (121552-61-2), (7.4) kasugamycin (6980-18-3), (7.5) kasugamycin hydrochloride hydrate (19408-46-9), (7.6) mepanipyrim (110235-47-7), (7.7) pyrimethanil (53112-28-0).

Particular preference is given to combinations comprising an inhibitor of the amino acid and/or protein biosynthesis selected from the group consisting of (7.3) cyprodinil, (7.6) mepanipyrim, (7.7) pyrimethanil.

Preference is further given to combinations comprising an inhibitor of the ATP production selected from the group consisting of [Group (8)]:

(8.1) fentin acetate (900-95-8), (8.2) fentin hydroxide (76-87-9), (8.3) silthiofam (175217-20-6).

Particular preference is given to combinations comprising the inhibitor of the ATP production, which is (8.3) silthiofam.

Preference is further given to combinations comprising an inhibitor of the cell wall synthesis selected from the group consisting of [Group (9)]:

(9.1) benthiavalicarb (177406-68-7), (9.2) dimethomorph (110488-70-5), (9.3) flumorph (211867-47-9), (9.4) iprovalicarb (140923-17-7), (9.5) mandipropamid (374726-62-2), (9.6) polyoxins, (9.7) polyoxorim, (9.8) prothiocarb, (9.9) validamycin A (37248-47-8), (9.10) valifenalate (283159-90-0), (9.11) N-[2-(4-{[3-(4-chlorophenyl)prop-2-yn-1-yl]oxy}-3-methoxyphenyl)ethyl]-N²-(methylsulfonyl)valinamide (220706-93-4).

Particular preference is given to combinations comprising an inhibitor of the cell wall synthesis selected from the group consisting of (9.1) benthiavalicarb, (9.4) iprovalicarb, (9.5) mandipropamid, (9.10) valifenalate.

Preference is further given to combinations comprising an inhibitor of the lipid and membrane synthesis selected from the group consisting of [Group (10)]:

(10.1) biphenyl (92-52-4), (10.2) chlozolate (84332-86-5), (10.3) edifenphos (17109-49-8), (10.4) etridiazole (2593-15-9), (10.5) iodocarb (55406-53-6), (10.6) iprobenfos (26087-47-8), (10.7) iprodione (36734-19-7), (10.8) isoprothiolane (50512-35-1), (10.9) procymidone (32809-16-8), (10.10) propamocarb (25606-41-1), (10.11) propamocarb-hydrochloride (25606-41-1), (10.12) pyrazophos (13457-18-6), (10.13) tolclufos-methyl (57018-04-9), (10.14) vinclozolin (50471-44-8).

Particular preference is given to combinations comprising an inhibitor of the lipid and membrane synthesis selected from the group consisting of (10.7) iprodione, (10.9) procymidone, (10.10) propamocarb, (10.11) propamocarb-hydrochloride.

Preference is further given to combinations comprising an inhibitor of the melanine biosynthesis selected from the group consisting of [Group (11)]:

(11.1) carpropamid (104030-54-8), (11.2) diclocymet (139920-32-4), (11.3) fenoxanil (115852-48-7), (11.4) phthalide (27355-22-2), (11.5) pyroquilon (57369-32-1), (11.6) tricyclazole (41814-78-2).

Preference is further given to combinations comprising an inhibitor of the nucleic acid synthesis selected from the group consisting of [Group (12)]:

(12.1) benalaxyl (71626-11-4), (12.2) benalaxyl-M (kiralaxyl) (98243-83-5), (12.3) bupirimate (41483-43-6), (12.4) clozylacon (67932-85-8), (12.5) dimethirimol (5221-53-4), (12.6) ethirimol (23947-60-6), (12.7) furalaxyl (57646-30-7), (12.8) hymexazol (10004-44-1), (12.9) metalaxyl (57837-19-1), (12.10) metalaxyl-M (mefenoxam) (70630-17-0), (12.11) ofurace (58810-48-3), (12.12) oxadixyl (77732-09-3), (12.13) oxolinic acid (14698-29-4).

Particular preference is given to combinations comprising an inhibitor of the nucleic acid synthesis selected from the group consisting of (12.1) benalaxyl, (12.2) benalaxyl-M (kiralaxyl), (12.9) metalaxyl (57837-19-1), (12.10) metalaxyl-M (mefenoxam).

Preference is further given to combinations comprising an inhibitor of the signal transduction selected from the group consisting of [Group (13)]:

(13.1) fenpiclonil (74738-17-3), (13.2) fludioxonil (131341-86-1), (13.3) quinoxifen (124495-18-7).

Preference is further given to combinations comprising a compound capable of acting as uncoupler selected from the group consisting of [Group (14)]:

(14.1) dinocap (131-72-6), (14.2) fluazinam (79622-59-6), (14.3) meptyldinocap (131-72-6), (14.4) binapacryl (485-31-4).

Preference is further given to combinations comprising a fungicide selected from the group consisting of [Group (15)]:

- (15.1) ametoctradin (865318-97-4), (15.2) benthiazole (21564-17-0), (15.3) bethoxazin (163269-30-5), (15.4) carvone (99-49-0), (15.5) chinomethionat (2439-01-2), (15.6) cyflufenamid (180409-60-3), (15.7) cymoxanil (57966-95-7), (15.8) dazomet (533-74-4), (15.9) debacarb (62732-91-6), (15.10) dichlorophen (97-23-4), (15.11) diclomezine (62865-36-5), (15.12) dicloran (99-30-9), (15.13) difenzoquat (43222-48-6), (15.14) diphenylamine (122-39-4), (15.15) ferimzone (89269-64-7), (15.16) flumetover (154025-04-4), (15.17) fluopicolide (239110-15-7), (15.18) fluoroimide (41205-21-4), (15.19) flusulfamide (106917-52-6), (15.20) fosetyl-Al, (15.21) hexachlorobenzene (118-74-1), (15.22) isotianil (224049-04-1), (15.23) methasulfocarb (66952-49-6), (15.24) methylisothiocyanate (556-61-6), (15.25) metrafenone (220899-03-6), (15.26) nitrothal-isopropyl (10552-74-6), (15.27) octhilinone (26530-20-1), (15.28) oxyfenthiin (34407-87-9), (15.29) propamocarb-fosetyl, (15.30) proquinazid (189278-12-4), (15.31) pyrrolnitrine (1018-71-9), (15.32) quintozone (82-68-8), (15.33) tecloftalam (76280-91-6), (15.34) tecnazene (117-18-0), (15.35) triazoxide (72459-58-6), (15.36) trichlamide (70193-21-4), (15.37) zarilamid (84527-51-5), (15.38) 8-hydroxyquinoline sulfate (134-31-6), (15.39) 2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine (13108-52-6), (15.40) 3,4,5-trichloropyridine-2,6-dicarbonitrile (17824-85-0), (15.41) 3-[5-(4-chlorophenyl)-2,3-dimethylisoxazolidin-3-yl]pyridine, (15.42) N-(4-chloro-2-nitrophenyl)-N-ethyl-4-methylbenzenesulfonamide (304911-98-6), (15.43) 2-butoxy-6-iodo-3-propyl-benzopyran-4-one, (15.44) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2,4-dichloronicotinamide, (15.45) N-[(5-bromo-3-chloropyridin-2-yl)methyl]-2,4-dichloronicotinamide, (15.46) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2-fluoro-4-iodonicotinamide, (15.47) N-(4-chlorobenzyl)-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, (15.48) N-[(4-chlorophenyl)(cyano)methyl]-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, (15.49) S-allyl-5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate, (15.50) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one (221451-58-7), (15.51) ethyl (2Z)-3-amino-2-cyano-3-phenylprop-2-enoate, (15.52) 5-amino-1,3,4-thiadiazole-2-thiol, (15.53) 1-[(4-methoxyphenoxy)methyl]-2,2-dimethylpropyl 1H-imidazole-1-carboxylate, (15.54) 3-chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, (15.55) 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine, (15.56) tebufloquin (376645-78-2), (15.57) flutianil, (15.58) (5-bromo-2-methoxy-4-methylpyridin-3-yl)(2,3,4-trimethoxy-6-methylphenyl)methanone (known from EP-A 1 559 320), (15.59) tolifenide, (15.60) N-{(Z)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide, (15.61) N-{(E)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide, (15.62) phosphorous acid and its salts, (15.63) 5-chloro-N'-phenyl-N'-prop-2-yn-1-ylthiophene-2-sulfonohydrazide, (15.64) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide, (15.65) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-thiazole-4-carboxamide, (15.66) pen-

tyl { 6-[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylidene]amino}oxy)methyl]pyridin-2-yl} carbamate,
 (15.67) capsimycin (70694-08-5), (15.68) chloroneb (2675-77-6), (15.69) cufraneb (11096-18-7), (15.70)
 cyprosulfamide (221667-31-8), (15.71) difenzoquat methylsulphate (43222-48-6), (15.72) ecomate,
 (15.73) fosetyl-calcium, (15.74) fosetyl-sodium (39148-16-8), (15.75) irumamycin (81604-73-1), (15.76)
 5 mildiomyacin (67527-71-3), (15.77) natamycin (7681-93-8), (15.78) nickel dimethyldithiocarbamate
 (15521-65-0), (15.79) oxamocarb, (15.80) pentachlorophenol and salts (87-86-5), (15.81) phenazine-1-
 carboxylic acid, (15.82) phenothrin, (15.83) propanosine-sodium (88498-02-6), (15.84) quinolin-8-ol
 (134-31-6), (15.85) 2-phenylphenol and salts (90-43-7), (15.86) 5-methyl-6-octyl-3,7-dihydro[1,2,4]tri-
 azolo[1,5-a]pyrimidin-7-amine, (15.87) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5R)-
 10 5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (15.88) 1-(4-{4-[(5R)-5-
 (2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-
 (trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (15.89) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-
 pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-
 carboxamide, (15.90) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl-4,5-
 15 dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (15.91) 2-[5-methyl-3-
 (trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-
 yl}piperidin-1-yl)ethanone, (15.92) 1-(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-
 1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (15.93) 1-(4-
 {4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-
 20 (trifluoromethyl)-1H-pyrazol-1-yl]ethanone (15.94) chlazaferone (688046-61-9), (15.95) 2-chloro-5-[2-
 chloro-1-(2,6-difluoro-4-methoxyphenyl)-4-methyl-1H-imidazol-5-yl]pyridine, (15.96) but-3-yn-1-yl{6-
 [(Z)-(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl} carbamate and
 salts thereof.

Particular preference is given to combinations comprising a fungicide selected from the group con-
 25 sisting of (15.1) ametoctradin, (15.17) fluopicolide, (15.20) fosetyl-Al, (15.22) isotianil, (15.25)
 metrafenone, (15.29) propamocarb-fosetylate, (15.35) triazoxide, (15.56) tebufloquin, and salts thereof.

In general component (B) is selected from the compounds mentioned in Table 4:

No.	Component B	No.	Component B
(1.1)	aldimorph	(5.24)	sulphur and sulphur preparations including calcium polysulphide
(1.2)	azaconazole	(5.25)	thiram
(1.3)	bitertanol	(5.26)	tolyfluanid
(1.4)	bromuconazole	(5.27)	zineb
(1.5)	cyproconazole	(5.28)	ziram
(1.6)	diclobutrazole	(5.29)	copper naphthenate
(1.7)	difenoconazole	(5.30)	dodine free base
(1.8)	diniconazole	(5.31)	fluorofolpet
(1.9)	diniconazole-M	(5.32)	guazatine acetate
(1.10)	dodemorph	(5.33)	metiram zinc
(1.11)	dodemorph acetate	(5.34)	propamidine
(1.12)	epoxiconazole	(6.1)	acibenzolar-S-methyl
(1.13)	etaconazole	(6.2)	probenzazole
(1.14)	fenarimol	(6.3)	tiadinil
(1.15)	fenbuconazole	(7.1)	andoprim
(1.16)	fenhexamid	(7.2)	blasticidin-S
(1.17)	fenpropidin	(7.3)	cyprodinyl
(1.18)	fenpropimorph	(7.4)	kasugamycin
(1.19)	fluquinconazole	(7.5)	kasugamycin hydrochloride hydrate
(1.20)	flurprimidol	(7.6)	mepanipyrim
(1.21)	flusilazole	(7.7)	pyrimethanil
(1.22)	flutriafol	(8.1)	fentin acetate
(1.23)	furconazole	(8.2)	fentin hydroxide
(1.24)	furconazole-cis	(8.3)	silthiofam
(1.25)	hexaconazole	(9.1)	benthiavalicarb
(1.26)	imazalil	(9.2)	dimethomorph
(1.27)	imazalil sulfate	(9.3)	flumorph
(1.28)	imibenconazole	(9.4)	iprovalicarb
(1.29)	ipconazole	(9.5)	mandipropamid
(1.30)	metconazole	(9.6)	polyoxins
(1.31)	myclobutanil	(9.7)	polyoxorim
(1.32)	naftifine	(9.8)	porthiocarb
(1.33)	nuarimol	(9.9)	validamycin A
(1.34)	oxpoconazole	(9.10)	valifenalate
(1.35)	paclobutrazol	(9.11)	N-[2-(4-{[3-(4-chlorophenyl)prop-2-yn-1-yl]oxy}-3-methoxyphenyl)ethyl]-N ² -(methylsulfonyl)valinamide
(1.36)	pefurazoate	(10.1)	biphenyl
(1.37)	penconazole	(10.2)	chlozolinate
(1.38)	piperalin	(10.3)	edifenfos
(1.39)	prochloraz	(10.4)	etridiazole
(1.40)	propiconazole	(10.5)	iodocarb
(1.41)	prothioconazole	(10.6)	iprobenfos
(1.42)	pyributicarb	(10.7)	iprodione
(1.43)	pyrifenox	(10.8)	isoprothiolane

No.	Component B	No.	Component B
(1.44)	quinconazole	(10.9)	procymidone
(1.45)	simeconazole	(10.10)	propamocarb
(1.46)	spiroxamine	(10.11)	propamocarb-hydrochloride
(1.47)	tebuconazole	(10.12)	pyrazophos
(1.48)	terbinafine	(10.13)	tolcofos-methyl
(1.49)	tetraconazole	(10.14)	vinclozolin
(1.50)	triadimefon	(11.1)	carpropamid
(1.51)	triadimenol	(11.2)	diclocymet
(1.52)	tridemorph	(11.3)	fenoxanil
(1.53)	triflumizole	(11.4)	phthalide
(1.54)	triforine	(11.5)	pyroquilon
(1.55)	triticonazole	(11.6)	tricyclazole
(1.56)	uniconazole	(12.1)	benalaxyl
(1.57)	viniconazole	(12.2)	benalaxyl-M (kiralaxyl)
(1.58)	1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)cycloheptanol	(12.3)	bupirimate
(1.59)	methyl 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazole-5-carboxylate	(12.4)	clozylacon
(1.60)	O-{1-[(4-methoxyphenoxy)methyl]-2,2-dimethylpropyl}-1H-imidazole-1-carbothioate	(12.5)	dimethirimol
(1.61)	N-ethyl-N-methyl-N'-{2-methyl-5-(difluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}-imidoformamid	(12.6)	ethirimol
(1.62)	N-ethyl-N-methyl-N'-{2-methyl-5-(trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}-imidoformamid	(12.7)	furalaxyl
(1.63)	voriconazole	(12.8)	hymexazol
(2.1)	diflumetorim	(12.9)	metalaxyl
(2.2)	bixafen	(12.10)	metalaxyl-M (mefenoxam)
(2.3)	boscalid	(12.11)	ofurace
(2.4)	carboxin	(12.12)	oxadixyl
(2.5)	fenfuram	(12.13)	oxolinic acid
(2.6)	fluopyram	(13.1)	fenpiclonil
(2.7)	flutolanil	(13.2)	fludioxonil
(2.8)	furametpyr	(13.3)	quinoxifen
(2.9)	furmecyclox	(14.1)	dinocap
(2.10)	isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR)	(14.2)	fluazinam
(2.11)	isopyrazam (syn epimeric racemate 1RS,4SR,9RS)	(14.3)	meptyldinocap
(2.12)	isopyrazam (syn-epimeric enantiomer 1R,4S,9R)	(14.4)	binapacryl
(2.13)	isopyrazam (syn-epimeric enantiomer 1S,4R,9S)	(15.1)	ametoctradin
(2.14)	isopyrazam (anti-epimeric racemate 1RS,4SR,9SR)	(15.2)	benthiazole

No.	Component B	No.	Component B
(2.15)	isopyrazam (anti-epimeric enantiomer 1R,4S,9S)	(15.3)	bethoxazin
(2.16)	isopyrazam (anti-epimeric enantiomer 1S,4R,9R)	(15.4)	carvone
(2.17)	mepronil	(15.5)	chinomethionat
(2.18)	oxycarboxin	(15.6)	cyflufenamid
(2.19)	penflufen	(15.7)	cymoxanil
(2.20)	penthiopyrad	(15.8)	dazomet
(2.21)	sedaxane	(15.9)	debacarb
(2.22)	thifluzamide	(15.10)	dichlorophen
(2.23)	1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide	(15.11)	diclomezine
(2.24)	3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide	(15.12)	dicloran
(2.25)	3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide	(15.13)	difenzoquat
(2.26)	1-methyl-3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide	(15.14)	diphenylamine
(2.27)	N-(4'-chlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide	(15.15)	ferimzone
(2.28)	N-(2',4'-dichlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide	(15.16)	flumetover
(2.29)	3-(difluoromethyl)-1-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide	(15.17)	fluopicolide
(2.30)	N-(2',5'-difluorobiphenyl-2-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide	(15.18)	fluoroimide
(2.31)	3-(difluoromethyl)-1-methyl-N-(4'-prop-1-yn-1-ylbiphenyl-2-yl)-1H-pyrazole-4-carboxamide	(15.19)	flusulfamide
(2.32)	5-fluoro-1,3-dimethyl-N-(4'-prop-1-yn-1-ylbiphenyl-2-yl)-1H-pyrazole-4-carboxamide	(15.20)	fosetyl-Al
(2.33)	2-chloro-N-(4'-prop-1-yn-1-ylbiphenyl-2-yl)nicotinamide	(15.21)	hexachlorobenzene
(2.34)	3-(difluoromethyl)-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide	(15.22)	isotianil
(2.35)	N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide	(15.23)	methasulfocarb

No.	Component B	No.	Component B
(2.36)	<i>N</i> -[4'-(ethinylbiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide]	(15.24)	methylisothiocyanate
(2.37)	<i>N</i> -(4'-ethinylbiphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide	(15.25)	metrafenone
(2.38)	2-chloro- <i>N</i> -(4'-ethinylbiphenyl-2-yl)-nicotinamide	(15.26)	nitrothal-isopropyl
(2.39)	2-chloro- <i>N</i> -[4'-(3,3-dimethylbut-1-in-1-yl)biphenyl-2-yl]-nicotinamide	(15.27)	octhilinone
(2.40)	4-(difluoromethyl)-2-methyl- <i>N</i> -[4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]-1,3-thiazole-5-carboxamide	(15.28)	oxyfenthiiin
(2.41)	5-fluoro- <i>N</i> -[4'-(3-hydroxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide	(15.29)	propamocarb-fosetylalte
(2.42)	2-chloro- <i>N</i> -[4'-(3-hydroxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-nicotinamide	(15.30)	proquinazid
(2.43)	3-difluoromethyl- <i>N</i> -[4'-(3-methoxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide	(15.31)	pyrrolnitrine
(2.44)	5-fluoro- <i>N</i> -[4'-(3-methoxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide	(15.32)	quintozene
(2.45)	3-(difluoromethyl)-1-methyl- <i>N</i> -(3',4',5'-trifluorobiphenyl-2-yl)-1H-pyrazole-4-carboxamide	(15.33)	tecloftalam
(2.46)	2-chloro- <i>N</i> -[4'-(3-methoxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-nicotinamide	(15.34)	tecnazene
(3.1)	amisulbrom	(15.35)	triazoxide
(3.2)	azoxystrobin	(15.36)	trichlamide
(3.3)	cyazofamid	(15.37)	zarilamid
(3.4)	dimoxystrobin	(15.38)	8-hydroxyquinoline sulfate
(3.5)	enestroburin	(15.39)	2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine
(3.6)	famoxadone	(15.40)	3,4,5-trichloropyridine-2,6-dicarbonitrile
(3.7)	fenamidone	(15.41)	3-[5-(4-chlorophenyl)-2,3-dimethylisoxazolidin-3-yl]pyridine
(3.8)	fluoxastrobin	(15.42)	<i>N</i> -(4-chloro-2-nitrophenyl)- <i>N</i> -ethyl-4-methylbenzenesulfonamide
(3.9)	kresoxim-methyl	(15.43)	2-butoxy-6-iodo-3-propylbenzopyran-4-one
(3.10)	metominostrobin	(15.44)	<i>N</i> -[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2,4-dichlornicotinamide
(3.11)	orysastrobin	(15.45)	<i>N</i> -[(5-bromo-3-chloropyridin-2-yl)methyl]-2,4-dichlornicotinamide
(3.12)	picoxystrobin	(15.46)	<i>N</i> -[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2-fluoro-4-iodonicotinamide

No.	Component B	No.	Component B
(3.13)	pyraclostrobin	(15.47)	N-(4-chlorobenzyl)-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide
(3.14)	pyrametostrobin	(15.48)	N-[(4-chlorophenyl)(cyano)methyl]-3-[3-methoxy-4-(prop-2-yn-1-yloxy)-phenyl]propanamide
(3.15)	pyraoxystrobin	(15.49)	S-allyl-5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate
(3.16)	pyribencarb	(15.50)	2,3-dibutyl-6-chlorothiemo[2,3-d]pyrimidin-4(3H)-one
(3.17)	trifloxystrobin	(15.51)	ethyl (2Z)-3-amino-2-cyano-3-phenyl-prop-2-enoate
(3.18)	5-methoxy-2-methyl-4-(2-{{[(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}-amino]oxy}methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one	(15.52)	5-amino-1,3,4-thiadiazole-2-thiol
(3.19)	(2E)-2-(2-{{[6-(3-chloro-2-methyl-phenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl}-2-(methoxyimino)-N-methylethanamide	(15.53)	1-[(4-methoxyphenoxy)methyl]-2,2-dimethylpropyl 1H-imidazole-1-carboxylate
(3.20)	2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-pyridine-3-carboxamide	(15.54)	3-chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine
(3.21)	(2E)-2-(methoxyimino)-N-methyl-2-(2-{{[(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino]oxy}methyl}-phenyl)-ethanamide	(15.55)	4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine
(3.22)	N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-(formylamino)-2-hydroxy-benzamide	(15.56)	tebufloquin
(3.23)	(2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]ethoxy}imino)methyl]phenyl}ethanamide	(15.57)	flutianil
(3.24)	(2E)-2-{2-[(E)-2-(2,6-dichlorophenyl)but-3-en-2-ylidene]amino}oxy)methyl-phenyl}-2-(methoxyimino)-N-methyl-ethanamide	(15.58)	(5-bromo-2-methoxy-4-methylpyridin-3-yl)(2,3,4-trimethoxy-6-methyl-phenyl)methanone
(3.25)	(2E)-2-{2-[(E)-1-(3-[(E)-1-fluoro-2-phenylvinyl]oxy}phenyl)ethylidene]-amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide	(15.59)	tolnifanide
(3.26)	methyl (2E)-2-{2-[(cyclopropyl[(4-methoxyphenyl)imino]methyl}thio)-methyl]phenyl}-3-methoxyacrylate	(15.60)	N-{(Z)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide
(4.1)	benomyl	(15.61)	N-{(E)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide
(4.2)	carbendazim	(15.62)	phosphorous acid and its salts
(4.3)	diethofencarb	(15.63)	5-chloro-N'-phenyl-N'-prop-2-yn-1-yl-thiophene-2-sulfonylhydrazide

No.	Component B	No.	Component B
(4.4)	ethaboxam	(15.64)	N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide
(4.5)	fuberidazole	(15.65)	N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-thiazole-4-carboxamide
(4.6)	pencycuron	(15.66)	pentyl {6-[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylidene]amino}oxy-methyl]pyridin-2-yl} carbamate
(4.7)	thiabendazole	(15.67)	capsimycin
(4.8)	thiophanate-methyl	(15.68)	chloroneb
(4.9)	zoxamide	(15.69)	cufraneb
(4.10)	5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine	(15.70)	cyprosulfamide
(5.1)	bordeaux mixture	(15.71)	difenzoquat methylsulphate
(5.2)	captafol	(15.72)	ecomate
(5.3)	captan	(15.73)	fosetyl-calcium
(5.4)	chorothalonil	(15.74)	fosetyl-sodium
(5.5)	dichlofluanid	(15.75)	irumamycin
(5.6)	dithianon	(15.76)	mildiomycin
(5.7)	dodine	(15.77)	natamycin
(5.8)	ferbam	(15.78)	nickel dimethyldithiocarbamate
(5.9)	folpet	(15.79)	oxamocarb
(5.10)	guazatine	(15.80)	pentachlorophenol and salts
(5.11)	iminoctadine	(15.81)	phenazine-1-carboxylic acid
(5.12)	iminoctadine triacetate	(15.82)	phenothrin
(5.13)	iminoctadine tris(albesilate)	(15.83)	propanosine-sodium
(5.14)	copper oxide	(15.84)	quinolin-8-ol
(5.15)	copper oxychlorid	(15.85)	2-phenylphenol and salts
(5.16)	copper hydroxide	(15.86)	5-methyl-6-octyl-3,7-dihydro[1,2,4]-triazolo[1,5-a]pyrimidin-7-amine
(5.17)	copper sulfate	(15.87)	2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5R)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone
(5.18)	mancopper	(15.88)	1-(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone

No.	Component B	No.	Component B
(5.19)	mancozeb	(15.89)	N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide
(5.20)	maneb	(15.90)	2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone
(5.21)	metiram	(15.91)	2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone
(5.22)	oxine copper	(15.92)	1-(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone
(5.23)	propineb	(15.93)	1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone
(1.64))	uniconazole-p (83657-17-4).	(4.13)	3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine (1002756-87-7)
(2.47)	N-[1-(2,4-dichlorophenyl)-1-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (1092400-95-7) (WO 2008148570).	(15.94)	chlazafenone (688046-61-9),
(3.27))	2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (173662-97-0)	(15.95)	2-chloro-5-[2-chloro-1-(2,6-difluoro-4-methoxyphenyl)-4-methyl-1H-imidazol-5-yl]pyridine
(3.28))	(2R)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (394657-24-0)	(15.96)	but-3-yn-1-yl{6-[(Z)-(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methylpyridin-2-yl}carbamate
(4.11))	chlorfenazole (3574-96-7)		
(4.12))	thiophanate (23564-06-9),		

Component (B) is preferably selected from the compounds mentioned in Table 5:

No.	Component B	No.	Component B
(1.3)	bitertanol	(3.13)	pyraclostrobin
(1.12)	epoxiconazole	(3.14)	pyrametostrobin
(1.16)	fenhexamid	(3.15)	pyraoxystrobin
(1.17)	fenpropidin	(3.17)	trifloxystrobin
(1.18)	fenpropimorph	(4.2)	carbendazim
(1.19)	fluquinconazole	(4.9)	zoxamide
(1.30)	metconazole	(4.10)	5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo-[1,5-a]pyrimidine
(1.41)	prothioconazole	(5.4)	chorothalonil
(1.46)	spiroxamine	(5.10)	guazatine
(1.47)	tebuconazole	(5.23)	propineb
(1.51)	triadimenol	(7.3)	cyprodinyl
(2.2)	bixafen	(7.6)	mepanipyrin
(2.3)	boscalid	(7.7)	pyrimethanil
(2.4)	Carboxin	(8.3)	silthiofam
(2.6)	fluopyram	(9.1)	benthiavalicarb
(2.10)	isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR)	(9.4)	iprovalicarb
(2.11)	isopyrazam (syn epimeric racemate 1RS,4SR,9RS)	(9.5)	mandipropamid
(2.12)	isopyrazam (syn-epimeric enantiomer 1R,4S,9R)	(9.10)	valifenalate
(2.13)	isopyrazam (syn-epimeric enantiomer 1S,4R,9S)	(10.7)	iprodione
(2.14)	isopyrazam (anti-epimeric racemate 1RS,4SR,9SR)	(10.9)	procymidone
(2.15)	isopyrazam (anti-epimeric enantiomer 1R,4S,9S)	(10.10)	propamocarb
(2.16)	isopyrazam (anti-epimeric enantiomer 1S,4R,9R)	(10.11)	propamocarb-hydrochloride
(2.19)	penflufen	(12.1)	benalaxyl
(2.20)	penthiopyrad	(12.2)	benalaxyl-M (kiralaxyl)
(2.21)	sedaxane	(12.9)	metalaxyl (57837-19-1)
(2.26)	1-methyl-3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide	(12.10)	metalaxyl-M (mefenoxam)
(3.2)	azoxystrobin	(15.1)	ametoctradin
(3.3)	cyazofamid	(15.17)	fluopicolide
(3.4)	dimoxystrobin	(15.20)	fosetyl-Al
(3.7)	fenamidone	(15.22)	isotianil
(3.8)	fluoxastrobil	(15.25)	metrafenone
(3.9)	kresoxim-methyl	(15.29)	propamocarb-fosetylalate
(3.10)	metominostrobin	(15.35)	triazoxide
(3.12)	picoxystrobin	(15.56)	tebufloquin

In a preferred embodiment this invention is directed to mixtures comprising the compound (I-1) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-1) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

- 5 In a preferred embodiment this invention is directed to mixtures comprising the compound (I-2) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-2) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

- 10 In a preferred embodiment this invention is directed to mixtures comprising the compound (I-3) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-3) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

In a preferred embodiment this invention is directed to mixtures comprising the compound (I-4) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

- 15 In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-4) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

In a preferred embodiment this invention is directed to mixtures comprising the compound (I-5) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

- 20 In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-5) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

In a preferred embodiment this invention is directed to mixtures comprising the compound (I-6) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-6) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

- 25 In a preferred embodiment this invention is directed to mixtures comprising the compound (I-7) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-7) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

In a preferred embodiment this invention is directed to mixtures comprising the compound (I-8) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

- 5 In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-8) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

In a preferred embodiment this invention is directed to mixtures comprising the compound (I-9) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

- 10 In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-9) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

In a preferred embodiment this invention is directed to mixtures comprising the compound (I-10) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-10) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

- 15 In a preferred embodiment this invention is directed to mixtures comprising the compound (I-11) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-11) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

- 20 In a preferred embodiment this invention is directed to mixtures comprising the compound (I-12) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-12) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

In a preferred embodiment this invention is directed to mixtures comprising the compound (I-13) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

- 25 In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-13) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

In a preferred embodiment this invention is directed to mixtures comprising the compound (I-14) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-14) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

- 5 In a preferred embodiment this invention is directed to mixtures comprising the compound (I-15) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-15) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

- 10 In a preferred embodiment this invention is directed to mixtures comprising the compound (I-16) as compound of formula (I) and one compound selected from the compounds listed in Table 4.

In a further preferred embodiment this invention is directed to mixtures comprising the compound (I-16) as compound of formula (I) and one compound selected from the compounds listed in Table 5.

- 15 If the active compounds in the active compound combinations according to the invention are present in certain weight ratios, the synergistic effect is particularly pronounced. However, the weight ratios of the active compounds in the active compound combinations can be varied within a relatively wide range.

- 20 In the combinations according to the invention the compounds (A) and (B) are present in a synergistically effective weight ratio of A:B in a range of 100:1 to 1:100, preferably in a weight ratio of 50:1 to 1:50, most preferably in a weight ratio of 20:1 to 1:20. Further ratios of A:B which can be used according to the present invention with increasing preference in the order given are: 95:1 to 1:95, 90:1 to 1:90, 85:1 to 1:85, 80:1 to 1:80, 75:1 to 1:75, 70:1 to 1:70, 65:1 to 1:65, 60:1 to 1:60, 55:1 to 1:55, 45:1 to 1:45, 40:1 to 1:40, 35:1 to 1:35, 30:1 to 1:30, 25:1 to 1:25, 15:1 to 1:15, 10:1 to 1:10, 5:1 to 1:5, 4:1 to 1:4, 3:1 to 1:3, 2:1 to 1:2.

- 25 Where a compound (A) or a compound (B) can be present in tautomeric form, such a compound is understood hereinabove and hereinbelow also to include, where applicable, corresponding tautomeric forms, even when these are not specifically mentioned in each case.

Compounds (A) or compounds (B) having at least one basic centre are capable of forming, for example, acid addition salts, e.g. with strong inorganic acids, such as mineral acids, e.g. perchloric acid, sulfuric acid, nitric acid, nitrous acid, a phosphoric acid or a hydrohalic acid, with strong or-

ganic carboxylic acids, such as unsubstituted substituted, e.g. halo-substituted, C₁-C₄ alkanecarboxylic acids, e.g. acetic acid, saturated or unsaturated dicarboxylic acids, e.g. oxalic, malonic, succinic, maleic, fumaric and phthalic acid, hydroxycarboxylic acids, e.g. ascorbic, lactic, malic, tartaric and citric acid, or benzoic acid, or with organic sulfonic acids, such as unsubstituted or substituted, e.g. halo-substituted, C₁-C₄alkane- or aryl-sulfonic acids, e.g. methane- or p-toluene-sulfonic acid. Compounds (A) or compounds (B) having at least one acid group are capable of forming, for example, salts with bases, e.g. metal salts, such as alkali metal or alkaline earth metal salts, e.g. sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, e.g. ethyl-, diethyl-, triethyl- or dimethyl-propyl-amine, or a mono-, di- or tri-hydroxy-lower alkylamine, e.g. mono-, di- or tri-ethanolamine. In addition, corresponding internal salts may optionally be formed. In the context of the invention, preference is given to agrochemically advantageous salts. In view of the close relationship between the compounds (A) or the compounds (B) in free form and in the form of their salts, hereinabove and herein below any reference to the free compounds (A) or free compounds (B) or to their salts should be understood as including also the corresponding salts or the free compounds (A) or free compounds (B), respectively, where appropriate and expedient. The equivalent also applies to tautomers of compounds (A) or compounds (B) and to their salts.

According to the invention the expression “combination” stands for the various combinations of compounds (A) and (B), for example in a single “ready-mix” form, in a combined spray mixture composed from separate formulations of the single active compounds, such as a “tank-mix”, and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. Preferably the order of applying the compounds (A) and (B) is not essential for working the present invention.

The present invention furthermore relates to compositions for combating/controlling undesirable microorganisms comprising the active compound combinations according to the invention. Preferably, the compositions are fungicidal compositions comprising agriculturally suitable auxiliaries, solvents, carriers, surfactants or extenders.

Furthermore the invention relates to a method of combating undesirable microorganisms, characterized in that the active compound combinations according to the invention are applied to the phytopathogenic fungi and/or their habitat.

According to the invention, carrier is to be understood as meaning a natural or synthetic, organic or inorganic substance which is mixed or combined with the active compounds for better applicability,

in particular for application to plants or plant parts or seeds. The carrier, which may be solid or liquid, is generally inert and should be suitable for use in agriculture.

Suitable solid or liquid carriers are: for example ammonium salts and natural ground minerals, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground
5 synthetic minerals, such as finely divided silica, alumina and natural or synthetic silicates, resins, waxes, solid fertilizers, water, alcohols, especially butanol, organic solvents, mineral oils and vegetable oils, and also derivatives thereof. It is also possible to use mixtures of such carriers. Solid carriers suitable for granules are: for example crushed and fractionated natural minerals, such as calcite, marble, pumice, sepiolite, dolomite, and also synthetic granules of inorganic and organic meals
10 and also granules of organic material, such as sawdust, coconut shells, maize cobs and tobacco stalks.

Suitable liquefied gaseous extenders or carriers are liquids which are gaseous at ambient temperature and under atmospheric pressure, for example aerosol propellants, such as butane, propane, nitrogen and carbon dioxide.

15 Tackifiers, such as carboxymethylcellulose and natural and synthetic polymers in the form of powders, granules and latices, such as gum arabic, polyvinyl alcohol, polyvinyl acetate, or else natural phospholipids, such as cephalins and lecithins and synthetic phospholipids can be used in the formulations. Other possible additives are mineral and vegetable oils and waxes, optionally modified.

If the extender used is water, it is also possible for example, to use organic solvents as auxiliary sol-
20 vents. Suitable liquid solvents are essentially: aromatic compounds, such as xylene, toluene or alkyl-naphthalenes, chlorinated aromatic compounds or chlorinated aliphatic hydrocarbons, such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons, such as cyclohexane or paraffins, for example mineral oil fractions, mineral and vegetable oils, alcohols, such as butanol or glycol, and also ethers and esters thereof, ketones, such as acetone, methyl ethyl ketone, methyl
25 isobutyl ketone or cyclohexanone, strongly polar solvents, such as dimethylformamide and dimethyl sulphoxide, and also water.

The compositions according to the invention may comprise additional further components, such as, for example, surfactants. Suitable surfactants are emulsifiers, dispersants or wetting agents having ionic or nonionic properties, or mixtures of these surfactants. Examples of these are salts of poly-
30 acrylic acid, salts of lignosulphonic acid, salts of phenolsulphonic acid or naphthalenesulphonic acid, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substi-

tuted phenols (preferably alkylphenols or arylphenols), salts of sulphosuccinic esters, taurine derivatives (preferably alkyl taurates), phosphoric esters of polyethoxylated alcohols or phenols, fatty esters of polyols, and derivatives of the compounds containing sulphates, sulphonates and phosphates. The presence of a surfactant is required if one of the active compounds and/or one of the inert carriers is insoluble in water and when the application takes place in water. The proportion of surfactants is between 5 and 40 per cent by weight of the composition according to the invention.

It is possible to use colorants such as inorganic pigments, for example iron oxide, titanium oxide, Prussian blue, and organic dyes, such as alizarin dyes, azo dyes and metal phthalocyanine dyes, and trace nutrients, such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.

If appropriate, other additional components may also be present, for example protective colloids, binders, adhesives, thickeners, thixotropic substances, penetrants, stabilizers, sequestering agents, complex formers. In general, the active compounds can be combined with any solid or liquid additive customarily used for formulation purposes.

In general, the compositions according to the invention comprise between 0.05 and 99 per cent by weight, 0.01 and 98 per cent by weight, preferable between 0.1 and 95 per cent by weight, particularly preferred between 0.5 and 90 per cent by weight of the active compound combination according to the invention, very particularly preferable between 10 and 70 per cent by weight.

The active compound combinations or compositions according to the invention can be used as such or, depending on their respective physical and/or chemical properties, in the form of their formulations or the use forms prepared therefrom, such as aerosols, capsule suspensions, cold-fogging concentrates, warm-fogging concentrates, encapsulated granules, fine granules, flowable concentrates for the treatment of seed, ready-to-use solutions, dustable powders, emulsifiable concentrates, oil-in-water emulsions, water-in-oil emulsions, macrogranules, microgranules, oil-dispersible powders, oil-miscible flowable concentrates, oil-miscible liquids, foams, pastes, pesticide-coated seed, suspension concentrates, suspoemulsion concentrates, soluble concentrates, suspensions, wettable powders, soluble powders, dusts and granules, water-soluble granules or tablets, water-soluble powders for the treatment of seed, wettable powders, natural products and synthetic substances impregnated with active compound, and also microencapsulations in polymeric substances and in coating materials for seed, and also ULV cold-fogging and warm-fogging formulations.

The formulations mentioned can be prepared in a manner known per se, for example by mixing the active compounds or the active compound combinations with at least one additive. Suitable additives are all cus-

tomary formulation auxiliaries, such as, for example, organic solvents, extenders, solvents or diluents, solid carriers and fillers, surfactants (such as adjuvants, emulsifiers, dispersants, protective colloids, wetting agents and tackifiers), dispersants and/or binders or fixatives, preservatives, dyes and pigments, defoamers, inorganic and organic thickeners, water repellents, if appropriate siccatives and UV stabilizers, gibberellins and also water and further processing auxiliaries. Depending on the formulation type to be prepared in each case, further processing steps such as, for example, wet grinding, dry grinding or granulation may be required.

The compositions according to the invention do not only comprise ready-to-use compositions which can be applied with suitable apparatus to the plant or the seed, but also commercial concentrates which have to be diluted with water prior to use.

The active compound combinations according to the invention can be present in (commercial) formulations and in the use forms prepared from these formulations as a mixture with other (known) active compounds, such as insecticides, attractants, sterilants, bactericides, acaricides, nematocides, fungicides, growth regulators, herbicides, fertilizers, safeners and Semiochemicals.

The treatment according to the invention of the plants and plant parts with the active compounds or compositions is carried out directly or by action on their surroundings, habitat or storage space using customary treatment methods, for example by dipping, spraying, atomizing, irrigating, evaporating, dusting, fogging, broadcasting, foaming, painting, spreading-on, watering (drenching), drip irrigating and, in the case of propagation material, in particular in the case of seeds, furthermore as a powder for dry seed treatment, a solution for seed treatment, a water-soluble powder for slurry treatment, by incrusting, by coating with one or more layers, etc. It is furthermore possible to apply the active compounds by the ultra-low volume method, or to inject the active compound preparation or the active compound itself into the soil.

The invention furthermore comprises a method for treating seed. The invention furthermore relates to seed treated according to one of the methods described in the preceding paragraph.

The active compounds or compositions according to the invention are especially suitable for treating seed. A large part of the damage to crop plants caused by harmful organisms is triggered by an infection of the seed during storage or after sowing as well as during and after germination of the plant. This phase is particularly critical since the roots and shoots of the growing plant are particularly sensitive, and even small damage may result in the death of the plant. Accordingly, there is great interest in protecting the seed and the germinating plant by using appropriate compositions.

The control of phytopathogenic fungi by treating the seed of plants has been known for a long time and is the subject of continuous improvements. However, the treatment of seed entails a series of problems which cannot always be solved in a satisfactory manner. Thus, it is desirable to develop methods for protecting the seed and the germinating plant which dispense with the additional application of crop protection agents after sowing or after the emergence of the plants or which at least considerably reduce additional application. It is furthermore desirable to optimize the amount of active compound employed in such a way as to provide maximum protection for the seed and the germinating plant from attack by phytopathogenic fungi, but without damaging the plant itself by the active compound employed. In particular, methods for the treatment of seed should also take into consideration the intrinsic fungicidal properties of transgenic plants in order to achieve optimum protection of the seed and the germinating plant with a minimum of crop protection agents being employed.

Accordingly, the present invention also relates in particular to a method for protecting seed and germinating plants against attack by phytopathogenic fungi by treating the seed with a composition according to the invention. The invention also relates to the use of the compositions according to the invention for treating seed for protecting the seed and the germinating plant against phytopathogenic fungi. Furthermore, the invention relates to seed treated with a composition according to the invention for protection against phytopathogenic fungi.

The control of phytopathogenic fungi which damage plants post-emergence is carried out primarily by treating the soil and the above-ground parts of plants with crop protection compositions. Owing to the concerns regarding a possible impact of the crop protection composition on the environment and the health of humans and animals, there are efforts to reduce the amount of active compounds applied.

One of the advantages of the present invention is that, because of the particular systemic properties of the compositions according to the invention, treatment of the seed with these compositions not only protects the seed itself, but also the resulting plants after emergence, from phytopathogenic fungi. In this manner, the immediate treatment of the crop at the time of sowing or shortly thereafter can be dispensed with.

It is also considered to be advantageous that the mixtures according to the invention can be used in particular also for transgenic seed where the plant growing from this seed is capable of expressing a protein which acts against pests. By treating such seed with the active compound combinations or compositions according to the invention, even by the expression of the, for example, insecticidal protein, certain pests may be controlled. Surprisingly, a further synergistic effect may be observed here, which additionally increases the effectiveness of the protection against attack by pests.

The compositions according to the invention are suitable for protecting seed of any plant variety employed in agriculture, in the greenhouse, in forests or in horticulture or viticulture. In particular, this takes the form of seed of cereals (such as wheat, barley, rye, triticale, millet, oats), maize (corn), cotton, soya bean, rice, potatoes, sunflowers, beans, coffee, beets (e.g. sugar beets and fodder beets),
5 peanuts, oilseed rape, poppies, olives, coconuts, cacao, sugar cane, tobacco, vegetables (such as tomatoes, cucumbers, onions and lettuce), lawn and ornamental plants (also see below). The treatment of seeds of cereals (such as wheat, barley, rye, triticale, and oats), maize (corn) and rice is of particular importance.

As also described further below, the treatment of transgenic seed with the active compound combinations or compositions according to the invention is of particular importance. This refers to the seed
10 of plants containing at least one heterologous gene which allows the expression of a polypeptide or protein having insecticidal properties. The heterologous gene in transgenic seed can originate, for example, from microorganisms of the species *Bacillus*, *Rhizobium*, *Pseudomonas*, *Serratia*, *Trichoderma*, *Clavibacter*, *Glomus* or *Gliocladium*. Preferably, this heterologous gene is from *Bacillus* sp.,
15 the gene product having activity against the European corn borer and/or the Western corn rootworm. Particularly preferably, the heterologous gene originates from *Bacillus thuringiensis*.

In the context of the present invention, the active compound combinations or compositions according to the invention are applied on their own or in a suitable formulation to the seed. Preferably, the seed is treated in a state in which it is sufficiently stable so that the treatment does not cause any damage.
20 In general, treatment of the seed may take place at any point in time between harvesting and sowing. Usually, the seed used is separated from the plant and freed from cobs, shells, stalks, coats, hairs or the flesh of the fruits. Thus, it is possible to use, for example, seed which has been harvested, cleaned and dried to a moisture content of less than 15 % by weight. Alternatively, it is also possible to use seed which, after drying, has been treated, for example, with water and then dried again.

25 When treating the seed, care must generally be taken that the amount of the composition according to the invention applied to the seed and/or the amount of further additives is chosen in such a way that the germination of the seed is not adversely affected, or that the resulting plant is not damaged. This must be borne in mind in particular in the case of active compounds which may have phytotoxic effects at certain application rates.

30 The compositions according to the invention can be applied directly, that is to say without comprising further components and without having been diluted. In general, it is preferable to apply the compositions to the seed in the form of a suitable formulation. Suitable formulations and methods for the treatment of seed

are known to the person skilled in the art and are described, for example, in the following documents: US 4,272,417 A, US 4,245,432 A, US 4,808,430 A, US 5,876,739 A, US 2003/0176428 A1, WO 2002/080675 A1, WO 2002/028186 A2.

5 The active compound combinations which can be used according to the invention can be converted into customary seed dressing formulations, such as solutions, emulsions, suspensions, powders, foams, slurries or other coating materials for seed, and also ULV formulations.

These formulations are prepared in a known manner by mixing the active compounds or active compound combinations with customary additives, such as, for example, customary extenders and also solvents or diluents, colorants, wetting agents, dispersants, emulsifiers, defoamers, preservatives,
10 secondary thickeners, adhesives, gibberellins and water as well.

Suitable colorants that may be present in the seed dressing formulations which can be used according to the invention include all colorants customary for such purposes. Use may be made both of pigments, of sparing solubility in water, and of dyes, which are soluble in water. Examples that may be mentioned include the colorants known under the designations Rhodamine B, C.I. Pigment Red 112,
15 and C.I. Solvent Red 1.

Suitable wetting agents that may be present in the seed dressing formulations which can be used according to the invention include all substances which promote wetting and are customary in the formulation of active agrochemical substances. With preference it is possible to use alkylnaphthalene-sulphonates, such as diisopropyl- or diisobutylnaphthalene-sulphonates.

20 Suitable dispersants and/or emulsifiers that may be present in the seed dressing formulations which can be used according to the invention include all nonionic, anionic, and cationic dispersants which are customary in the formulation of active agrochemical substances. With preference, it is possible to use nonionic or anionic dispersants or mixtures of nonionic or anionic dispersants. Particularly suitable nonionic dispersants are ethylene oxide-propylene oxide block polymers, alkylphenol polyglycol ethers, and tristerylphenol polyglycol ethers, and their phosphated or sulphated derivatives.
25 Particularly suitable anionic dispersants are lignosulphonates, polyacrylic salts, and arylsulphonate-formaldehyde condensates.

Defoamers that may be present in the seed dressing formulations to be used according to the invention include all foam-inhibiting compounds which are customary in the formulation of agrochemically active
30 compounds. Preference is given to using silicone defoamers, magnesium stearate, silicone emulsions,

long-chain alcohols, fatty acids and their salts and also organofluorine compounds and mixtures thereof.

Preservatives that may be present in the seed dressing formulations to be used according to the invention include all compounds which can be used for such purposes in agrochemical compositions. By way of example, mention may be made of dichlorophen and benzyl alcohol hemiformal.

Secondary thickeners that may be present in the seed dressing formulations to be used according to the invention include all compounds which can be used for such purposes in agrochemical compositions. Preference is given to cellulose derivatives, acrylic acid derivatives, polysaccharides, such as xanthan gum or Veegum, modified clays, phyllosilicates, such as attapulgite and bentonite, and also finely divided silicic acids.

Suitable adhesives that may be present in the seed dressing formulations to be used according to the invention include all customary binders which can be used in seed dressings. Polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose may be mentioned as being preferred.

Suitable gibberellins that may be present in the seed dressing formulations to be used according to the invention are preferably the gibberellins A1, A3 (= gibberellic acid), A4 and A7; particular preference is given to using gibberellic acid. The gibberellins are known (cf. R. Wegler "Chemie der Pflanzenschutz- und Schädlingsbekämpfungsmittel" [Chemistry of Crop Protection Agents and Pesticides], Vol. 2, Springer Verlag, 1970, pp. 401-412).

The seed dressing formulations which can be used according to the invention may be used directly or after dilution with water beforehand to treat seed of any of a very wide variety of types. The seed dressing formulations which can be used according to the invention or their dilute preparations may also be used to dress seed of transgenic plants. In this context, synergistic effects may also arise in interaction with the substances formed by expression.

Suitable mixing equipment for treating seed with the seed dressing formulations which can be used according to the invention or the preparations prepared from them by adding water includes all mixing equipment which can commonly be used for dressing. The specific procedure adopted when dressing comprises introducing the seed into a mixer, adding the particular desired amount of seed dressing formulation, either as it is or following dilution with water beforehand, and carrying out mixing until the formulation is uniformly distributed on the seed. Optionally, a drying operation follows.

The active compounds or compositions according to the invention have strong microbicidal activity and can be used for controlling unwanted microorganisms, such as fungi and bacteria, in crop protection and material protection.

In crop protection, fungicides can be used for controlling Plasmodiophoromycetes, Oomycetes, Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes.

In crop protection, bactericides can be used for controlling Pseudomonadaceae, Rhizobiaceae, Enterobacteriaceae, Corynebacteriaceae and Streptomycetaceae.

The fungicidal compositions according to the invention can be used for the curative or protective control of phytopathogenic fungi. Accordingly, the invention also relates to curative and protective methods for controlling phytopathogenic fungi using the active compound combinations or compositions according to the invention, which are applied to the seed, the plant or plant parts, the fruit or the soil in which the plants grow. Preference is given to application onto the plant or the plant parts, the fruits or the soil in which the plants grow.

The compositions according to the invention for combating phytopathogenic fungi in crop protection comprise an active, but non-phytotoxic amount of the compounds according to the invention. "Active, but non-phytotoxic amount" shall mean an amount of the composition according to the invention which is sufficient to control or to completely kill the plant disease caused by fungi, which amount at the same time does not exhibit noteworthy symptoms of phytotoxicity. These application rates generally may be varied in a broader range, which rate depends on several factors, e.g. the phytopathogenic fungi, the plant or crop, the climatic conditions and the ingredients of the composition according to the invention.

The fact that the active compounds, at the concentrations required for the controlling of plant diseases, are well tolerated by plants permits the treatment of aerial plant parts, of vegetative propagation material and seed, and of the soil.

According to the invention, it is possible to treat all plants and parts of plants. Plants are to be understood here as meaning all plants and plant populations, such as wanted and unwanted wild plants or crop plants (including naturally occurring crop plants). Crop plants can be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including plant cultivars which can or cannot be protected by plant variety protection rights. Parts of plants are to be understood as meaning all above-ground and below-ground parts and organs of the plants, such as shoot, leaf, flower and root, ex-

amples which may be mentioned being leaves, needles, stems, trunks, flowers, fruit bodies, fruits and seeds and also roots, tubers and rhizomes. Plant parts also include harvested material and vegetative and generative propagation material, for example seedlings, tubers, rhizomes, cuttings and seeds. Preference is given to the treatment of the plants and the above-ground and below-ground parts and organs of the plants, such as shoot, leaf, flower and root, examples which may be mentioned being leaves, needles, stems, trunks, flowers, and fruits.

The active compounds of the invention, in combination with good plant tolerance and favourable toxicity to warm-blooded animals and being tolerated well by the environment, are suitable for protecting plants and plant organs, for increasing the harvest yields, for improving the quality of the harvested material. They may be preferably employed as crop protection agents. They are active against normally sensitive and resistant species and against all or some stages of development.

The following plants may be mentioned as plants which can be treated according to the invention: cotton, flax, grapevines, fruit, vegetable, such as *Rosaceae sp.* (for example pomaceous fruit, such as apples and pears, but also stone fruit, such as apricots, cherries, almonds and peaches and soft fruit such as strawberries), *Ribesioideae sp.*, *Juglandaceae sp.*, *Betulaceae sp.*, *Anacardiaceae sp.*, *Fagaceae sp.*, *Moraceae sp.*, *Oleaceae sp.*, *Actinidaceae sp.*, *Lauraceae sp.*, *Musaceae sp.* (for example banana trees and plantations), *Rubiaceae sp.* (for example coffee), *Theaceae sp.*, *Sterculiaceae sp.*, *Rutaceae sp.* (for example lemons, oranges and grapefruit), *Solanaceae sp.* (for example tomatoes), *Liliaceae sp.*, *Asteraceae sp.* (for example lettuce), *Umbelliferae sp.*, *Cruciferae sp.*, *Chenopodiaceae sp.*, *Cucurbitaceae sp.* (for example cucumbers), *Alliaceae sp.* (for example leek, onions), *Papilionaceae sp.* (for example peas); major crop plants, such as *Gramineae sp.* (for example maize, lawn, cereals such as wheat, rye, rice, barley, oats, millet and triticale), *Asteraceae sp.* (for example sunflowers), *Brassicaceae sp.* (for example white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, garden radish, and also oilseed rape, mustard, horseradish and cress), *Fabaceae sp.* (for example beans, peas, peanuts), *Papilionaceae sp.* (for example soya beans), *Solanaceae sp.* (for example potatoes), *Chenopodiaceae sp.* (for example sugar beet, fodder beet, Swiss chard, beetroot); crop plants and ornamental plants in garden and forest; and also in each case genetically modified varieties of these plants.

As already mentioned above, it is possible to treat all plants and their parts according to the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding methods, such as crossing or protoplast fusion, and parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering methods, if appropriate in combination with conventional methods (genetically modified

organisms), and parts thereof are treated. The terms "parts", "parts of plants" and "plant parts" have been explained above. Particularly preferably, plants of the plant cultivars which are in each case commercially available or in use are treated according to the invention. Plant cultivars are to be understood as meaning plants having novel properties ("traits") which have been obtained by conventional breeding, by mutagenesis or by recombinant DNA techniques. These can be cultivars, bio- or genotypes.

The method of treatment according to the invention is used in the treatment of genetically modified organisms (GMOs), e.g. plants or seeds. Genetically modified plants (or transgenic plants) are plants of which a heterologous gene has been stably integrated into the genome. The expression "heterologous gene" essentially means a gene which is provided or assembled outside the plant and when introduced in the nuclear, chloroplastic or mitochondrial genome gives the transformed plant new or improved agronomic or other properties by expressing a protein or polypeptide of interest or by down regulating or silencing other gene(s) which are present in the plant (using for example, antisense technology, co-suppression technology or RNA interference – RNAi - technology). A heterologous gene that is located in the genome is also called a transgene. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.

Depending on the plant species or plant cultivars, their location and growth conditions (soils, climate, vegetation period, diet), the treatment according to the invention may also result in super-additive ("synergistic") effects. Thus, for example, reduced application rates and/or a widening of the activity spectrum and/or an increase in the activity of the active compounds and compositions which can be used according to the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, bigger fruits, larger plant height, greener leaf color, earlier flowering, higher quality and/or a higher nutritional value of the harvested products, higher sugar concentration within the fruits, better storage stability and/or processability of the harvested products are possible, which exceed the effects which were actually to be expected.

At certain application rates, the active compound combinations according to the invention may also have a strengthening effect in plants. Accordingly, they are also suitable for mobilizing the defense system of the plant against attack by unwanted phytopathogenic fungi and/ or microorganisms and/or viruses. This may, if appropriate, be one of the reasons of the enhanced activity of the combinations according to the invention, for example against fungi. Plant-strengthening (resistance-inducing) substances are to be understood as meaning, in the present context, those substances or combinations of substances which are

capable of stimulating the defense system of plants in such a way that, when subsequently inoculated with unwanted phytopathogenic fungi and/or microorganisms and/or viruses, the treated plants display a substantial degree of resistance to these phytopathogenic fungi and/or microorganisms and/or viruses. Thus, the substances according to the invention can be employed for protecting plants against attack by the abovementioned pathogens within a certain period of time after the treatment. The period of time within which protection is effected generally extends from 1 to 10 days, preferably 1 to 7 days, after the treatment of the plants with the active compounds.

Plants and plant cultivars which are preferably to be treated according to the invention include all plants which have genetic material which impart particularly advantageous, useful traits to these plants (whether obtained by breeding and/or biotechnological means).

Plants and plant cultivars which are also preferably to be treated according to the invention are resistant against one or more biotic stresses, i.e. said plants show a better defense against animal and microbial pests, such as against nematodes, insects, mites, phytopathogenic fungi, bacteria, viruses and/or viroids.

Plants and plant cultivars which may also be treated according to the invention are those plants which are resistant to one or more abiotic stresses. Abiotic stress conditions may include, for example, drought, cold temperature exposure, heat exposure, osmotic stress, flooding, increased soil salinity, increased mineral exposure, ozon exposure, high light exposure, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients, shade avoidance.

Plants and plant cultivars which may also be treated according to the invention, are those plants characterized by enhanced yield characteristics. Increased yield in said plants can be the result of, for example, improved plant physiology, growth and development, such as water use efficiency, water retention efficiency, improved nitrogen use, enhanced carbon assimilation, improved photosynthesis, increased germination efficiency and accelerated maturation. Yield can furthermore be affected by improved plant architecture (under stress and non-stress conditions), including but not limited to, early flowering, flowering control for hybrid seed production, seedling vigor, plant size, internode number and distance, root growth, seed size, fruit size, pod size, pod or ear number, seed number per pod or ear, seed mass, enhanced seed filling, reduced seed dispersal, reduced pod dehiscence and lodging resistance. Further yield traits include seed composition, such as carbohydrate content, protein content, oil content and composition, nutritional value, reduction in anti-nutritional compounds, improved processability and better storage stability.

Plants that may be treated according to the invention are hybrid plants that already express the characteristic of heterosis or hybrid vigor which results in generally higher yield, vigor, health and resistance towards biotic and abiotic stress factors. Such plants are typically made by crossing an inbred male-sterile parent line (the female parent) with another inbred male-fertile parent line (the male parent). Hybrid seed is typically harvested from the male sterile plants and sold to growers. Male sterile plants can sometimes (e.g. in corn) be produced by detasseling, i.e. the mechanical removal of the male reproductive organs (or males flowers) but, more typically, male sterility is the result of genetic determinants in the plant genome. In that case, and especially when seed is the desired product to be harvested from the hybrid plants it is typically useful to ensure that male fertility in the hybrid plants is fully restored. This can be accomplished by ensuring that the male parents have appropriate fertility restorer genes which are capable of restoring the male fertility in hybrid plants that contain the genetic determinants responsible for male-sterility. Genetic determinants for male sterility may be located in the cytoplasm. Examples of cytoplasmic male sterility (CMS) were for instance described in Brassica species. However, genetic determinants for male sterility can also be located in the nuclear genome. Male sterile plants can also be obtained by plant biotechnology methods such as genetic engineering. A particularly useful means of obtaining male-sterile plants is described in WO 89/10396 in which, for example, a ribonuclease such as barnase is selectively expressed in the tapetum cells in the stamens. Fertility can then be restored by expression in the tapetum cells of a ribonuclease inhibitor such as barstar.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may be treated according to the invention are herbicide-tolerant plants, i.e. plants made tolerant to one or more given herbicides. Such plants can be obtained either by genetic transformation, or by selection of plants containing a mutation imparting such herbicide tolerance.

Herbicide-tolerant plants are for example glyphosate-tolerant plants, i.e. plants made tolerant to the herbicide glyphosate or salts thereof. Plants can be made tolerant to glyphosate through different means. For example, glyphosate-tolerant plants can be obtained by transforming the plant with a gene encoding the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS). Examples of such EPSPS genes are the AroA gene (mutant CT7) of the bacterium *Salmonella typhimurium*, the CP4 gene of the bacterium *Agrobacterium sp*, the genes encoding a Petunia EPSPS, a Tomato EPSPS, or an Eleusine EPSPS. It can also be a mutated EPSPS. Glyphosate-tolerant plants can also be obtained by expressing a gene that encodes a glyphosate oxido-reductase enzyme. Glyphosate-tolerant plants can also be obtained by expressing a gene that encodes a glyphosate acetyl transferase en-

zyme. Glyphosate-tolerant plants can also be obtained by selecting plants containing naturally-occurring mutations of the above-mentioned genes.

Other herbicide resistant plants are for example plants that are made tolerant to herbicides inhibiting the enzyme glutamine synthase, such as bialaphos, phosphinothricin or glufosinate. Such plants can be obtained by expressing an enzyme detoxifying the herbicide or a mutant glutamine synthase enzyme that is resistant to inhibition. One such efficient detoxifying enzyme is an enzyme encoding a phosphinothricin acetyltransferase (such as the bar or pat protein from *Streptomyces* species). Plants expressing an exogenous phosphinothricin acetyltransferase are also described.

Further herbicide-tolerant plants are also plants that are made tolerant to the herbicides inhibiting the enzyme hydroxyphenylpyruvatedioxygenase (HPPD). Hydroxyphenylpyruvatedioxygenases are enzymes that catalyze the reaction in which para-hydroxyphenylpyruvate (HPP) is transformed into homogentisate. Plants tolerant to HPPD-inhibitors can be transformed with a gene encoding a naturally-occurring resistant HPPD enzyme, or a gene encoding a mutated HPPD enzyme. Tolerance to HPPD-inhibitors can also be obtained by transforming plants with genes encoding certain enzymes enabling the formation of homogentisate despite the inhibition of the native HPPD enzyme by the HPPD-inhibitor. Tolerance of plants to HPPD inhibitors can also be improved by transforming plants with a gene encoding an enzyme prephenate dehydrogenase in addition to a gene encoding an HPPD-tolerant enzyme.

Still further herbicide resistant plants are plants that are made tolerant to acetolactate synthase (ALS) inhibitors. Known ALS-inhibitors include, for example, sulfonylurea, imidazolinone, triazolopyrimidines, pyrimidinyoxy(thio)benzoates, and/or sulfonylaminocarbonyltriazolinone herbicides. Different mutations in the ALS enzyme (also known as acetohydroxyacid synthase, AHAS) are known to confer tolerance to different herbicides and groups of herbicides. The production of sulfonylurea-tolerant plants and imidazolinone-tolerant plants is described in WO 1996/033270. Other imidazolinone-tolerant plants are also described. Further sulfonylurea- and imidazolinone-tolerant plants are also described in for example WO 2007/024782.

Other plants tolerant to imidazolinone and/or sulfonylurea can be obtained by induced mutagenesis, selection in cell cultures in the presence of the herbicide or mutation breeding as described for example for soybeans, for rice, for sugar beet, for lettuce, or for sunflower.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are insect-resistant transgenic plants, i.e. plants

made resistant to attack by certain target insects. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such insect resistance.

An “insect-resistant transgenic plant”, as used herein, includes any plant containing at least one transgene comprising a coding sequence encoding:

- 5 1) an insecticidal crystal protein from *Bacillus thuringiensis* or an insecticidal portion thereof, such as the insecticidal crystal proteins listed online at:

http://www.lifesci.sussex.ac.uk/Home/Neil_Crickmore/Bt/, or insecticidal portions thereof, e.g., proteins of the Cry protein classes Cry1Ab, Cry1Ac, Cry1F, Cry2Ab, Cry3Aa, or Cry3Bb or insecticidal portions thereof; or

- 10 2) a crystal protein from *Bacillus thuringiensis* or a portion thereof which is insecticidal in the presence of a second other crystal protein from *Bacillus thuringiensis* or a portion thereof, such as the binary toxin made up of the Cry34 and Cry35 crystal proteins; or

- 3) a hybrid insecticidal protein comprising parts of different insecticidal crystal proteins from *Bacillus thuringiensis*, such as a hybrid of the proteins of 1) above or a hybrid of the proteins of 2) above, e.g., the Cry1A.105 protein produced by corn event MON98034 (WO 15 2007/027777); or

- 4) a protein of any one of 1) to 3) above wherein some, particularly 1 to 10, amino acids have been replaced by another amino acid to obtain a higher insecticidal activity to a target insect species, and/or to expand the range of target insect species affected, and/or because of 20 changes introduced into the encoding DNA during cloning or transformation, such as the Cry3Bb1 protein in corn events MON863 or MON88017, or the Cry3A protein in corn event MIR604;

- 5) an insecticidal secreted protein from *Bacillus thuringiensis* or *Bacillus cereus*, or an insecticidal portion thereof, such as the vegetative insecticidal (VIP) proteins listed at:

25 http://www.lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/vip.html, e.g. proteins from the VIP3Aa protein class; or

- 6) secreted protein from *Bacillus thuringiensis* or *Bacillus cereus* which is insecticidal in the presence of a second secreted protein from *Bacillus thuringiensis* or *B. cereus*, such as the binary toxin made up of the VIP1A and VIP2A proteins; or

- 7) hybrid insecticidal protein comprising parts from different secreted proteins from *Bacillus thuringiensis* or *Bacillus cereus*, such as a hybrid of the proteins in 1) above or a hybrid of the proteins in 2) above; or
- 8) protein of any one of 1) to 3) above wherein some, particularly 1 to 10, amino acids have been replaced by another amino acid to obtain a higher insecticidal activity to a target insect species, and/or to expand the range of target insect species affected, and/or because of changes introduced into the encoding DNA during cloning or transformation (while still encoding an insecticidal protein), such as the VIP3Aa protein in cotton event COT102.

Of course, an insect-resistant transgenic plant, as used herein, also includes any plant comprising a combination of genes encoding the proteins of any one of the above classes 1 to 8. In one embodiment, an insect-resistant plant contains more than one transgene encoding a protein of any one of the above classes 1 to 8, to expand the range of target insect species affected when using different proteins directed at different target insect species, or to delay insect resistance development to the plants by using different proteins insecticidal to the same target insect species but having a different mode of action, such as binding to different receptor binding sites in the insect.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are tolerant to abiotic stresses. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such stress resistance. Particularly useful stress tolerance plants include:

- a. plants which contain a transgene capable of reducing the expression and/or the activity of poly(ADP-ribose)polymerase (PARP) gene in the plant cells or plants
- b. plants which contain a stress tolerance enhancing transgene capable of reducing the expression and/or the activity of the PARP encoding genes of the plants or plants cells.
- c. plants which contain a stress tolerance enhancing transgene coding for a plant-functional enzyme of the nicotinamide adenine dinucleotide salvage synthesis pathway including nicotinamidase, nicotinate phosphoribosyltransferase, nicotinic acid mononucleotide adenylyl transferase, nicotinamide adenine dinucleotide synthetase or nicotine amide phosphoribosyltransferase.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention show altered quantity, quality and/or storage-

stability of the harvested product and/or altered properties of specific ingredients of the harvested product such as :

- 1) transgenic plants which synthesize a modified starch, which in its physical-chemical characteristics, in particular the amylose content or the amylose/amylopectin ratio, the degree of branching, the average chain length, the side chain distribution, the viscosity behaviour, the gelling strength, the starch grain size and/or the starch grain morphology, is changed in comparison with the synthesised starch in wild type plant cells or plants, so that this is better suited for special applications.
 - 2) transgenic plants which synthesize non starch carbohydrate polymers or which synthesize non starch carbohydrate polymers with altered properties in comparison to wild type plants without genetic modification. Examples are plants producing polyfructose, especially of the inulin and levan-type, plants producing alpha 1,4 glucans, plants producing alpha-1,6 branched alpha-1,4-glucans, plants producing alternan,
 - 3) transgenic plants which produce hyaluronan.
- 15 Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as cotton plants, with altered fiber characteristics. Such plants can be obtained by genetic transformation or by selection of plants contain a mutation imparting such altered fiber characteristics and include:
- a) Plants, such as cotton plants, containing an altered form of cellulose synthase genes,
 - 20 b) Plants, such as cotton plants, containing an altered form of rsw2 or rsw3 homologous nucleic acids,
 - c) Plants, such as cotton plants, with increased expression of sucrose phosphate synthase,
 - d) Plants, such as cotton plants, with increased expression of sucrose synthase,
 - e) Plants, such as cotton plants, wherein the timing of the plasmodesmatal gating at the basis of the fiber cell is altered, e.g. through downregulation of fiberselective β 1,3-glucanase,
 - 25 f) Plants, such as cotton plants, having fibers with altered reactivity, e.g. through the expression of N-acetylglucosaminetransferase gene including nodC and chitinsynthase genes.

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered oil profile characteristics. Such plants can be obtained by genetic transformation or by selection of plants contain a mutation imparting such altered oil characteristics and include:

- a) Plants, such as oilseed rape plants, producing oil having a high oleic acid content,
- b) Plants such as oilseed rape plants, producing oil having a low linolenic acid content,
- c) Plant such as oilseed rape plants, producing oil having a low level of saturated fatty acids.

Particularly useful transgenic plants which may be treated according to the invention are plants which comprise one or more genes which encode one or more toxins, such as the following which are sold under the trade names YIELD GARD® (for example maize, cotton, soya beans), KnockOut® (for example maize), BiteGard® (for example maize), Bt-Xtra® (for example maize), StarLink® (for example maize), Bollgard® (cotton), Nucotn® (cotton), Nucotn 33B®(cotton), NatureGard® (for example maize), Protecta® and NewLeaf® (potato). Examples of herbicide-tolerant plants which may be mentioned are maize varieties, cotton varieties and soya bean varieties which are sold under the trade names Roundup Ready® (tolerance to glyphosate, for example maize, cotton, soya bean), Liberty Link® (tolerance to phosphinotricin, for example oilseed rape), IMI® (tolerance to imidazolinones) and STS® (tolerance to sulphonylureas, for example maize). Herbicide-resistant plants (plants bred in a conventional manner for herbicide tolerance) which may be mentioned include the varieties sold under the name Clearfield® (for example maize).

Particularly useful transgenic plants which may be treated according to the invention are plants containing transformation events, or combination of transformation events, that are listed for example in the databases from various national or regional regulatory agencies (see for example

http://gmoinfo.jrc.it/gmp_browse.aspx and <http://www.agbios.com/dbase.php>).

In material protection the substances of the invention may be used for the protection of technical materials against infestation and destruction by undesirable fungi and/or microorganisms.

Technical materials are understood to be in the present context non-living materials that have been prepared for use in engineering. For example, technical materials that are to be protected against micro-biological change or destruction by the active materials of the invention can be adhesives, glues,

paper and cardboard, textiles, carpets, leather, wood, paint and plastic articles, cooling lubricants and other materials that can be infested or destroyed by micro-organisms. Within the context of materials to be protected are also parts of production plants and buildings, for example cooling circuits, cooling and heating systems, air conditioning and ventilation systems, which can be adversely affected by the propagation of fungi and/or microorganisms. Within the context of the present invention, preferably mentioned as technical materials are adhesives, glues, paper and cardboard, leather, wood, paints, cooling lubricants and heat exchanger liquids, particularly preferred is wood. The combinations according to the invention can prevent disadvantageous effects like decaying, dis- and decoloring, or molding. The active compound combinations and compositions according to the invention can likewise be employed for protecting against colonization of objects, in particular ship hulls, sieves, nets, buildings, quays and signalling installations, which are in contact with sea water or brackish water.

The method of treatment according to the invention can also be used in the field of protecting storage goods against attack of fungi and microorganisms. According to the present invention, the term “storage goods” is understood to denote natural substances of vegetable or animal origin and their processed forms, which have been taken from the natural life cycle and for which long-term protection is desired. Storage goods of vegetable origin, such as plants or parts thereof, for example stalks, leaves, tubers, seeds, fruits or grains, can be protected in the freshly harvested state or in processed form, such as pre-dried, moistened, comminuted, ground, pressed or roasted. Also falling under the definition of storage goods is timber, whether in the form of crude timber, such as construction timber, electricity pylons and barriers, or in the form of finished articles, such as furniture or objects made from wood. Storage goods of animal origin are hides, leather, furs, hairs and the like. The combinations according to the present invention can prevent disadvantageous effects such as decay, discoloration or mold. Preferably “storage goods” is understood to denote natural substances of vegetable origin and their processed forms, more preferably fruits and their processed forms, such as pomes, stone fruits, soft fruits and citrus fruits and their processed forms.

Some pathogens of fungal diseases which can be treated according to the invention may be mentioned by way of example, but not by way of limitation:

Diseases caused by powdery mildew pathogens, such as, for example, *Blumeria* species, such as, for example, *Blumeria graminis*; *Podosphaera* species, such as, for example, *Podosphaera leucotricha*; *Sphaerotheca* species, such as, for example, *Sphaerotheca fuliginea*; *Uncinula* species, such as, for example, *Uncinula necator*;

Diseases caused by rust disease pathogens, such as, for example, *Gymnosporangium* species, such as, for example, *Gymnosporangium sabinae*; *Hemileia* species, such as, for example, *Hemileia vastatrix*; *Phakopsora* species, such as, for example, *Phakopsora pachyrhizi* and *Phakopsora meibomiae*; *Puccinia* species, such as, for example, *Puccinia recondita* or *Puccinia triticina*; *Uromyces* species, such as, for example, *Uromyces appendiculatus*;

Diseases caused by pathogens from the group of the Oomycetes, such as, for example, *Bremia* species, such as, for example, *Bremia lactucae*; *Peronospora* species, such as, for example, *Peronospora pisi* or *P. brassicae*; *Phytophthora* species, such as, for example *Phytophthora infestans*; *Plasmopara* species, such as, for example, *Plasmopara viticola*; *Pseudoperonospora* species, such as, for example, *Pseudoperonospora humuli* or *Pseudoperonospora cubensis*; *Pythium* species, such as, for example, *Pythium ultimum*;

Leaf blotch diseases and leaf wilt diseases caused, for example, by *Alternaria* species, such as, for example, *Alternaria solani*; *Cercospora* species, such as, for example, *Cercospora beticola*; *Cladosporium* species, such as, for example, *Cladosporium cucumerinum*; *Cochliobolus* species, such as, for example, *Cochliobolus sativus* (conidia form: *Drechslera*, Syn: *Helminthosporium*); *Colletotrichum* species, such as, for example, *Colletotrichum lindemuthianum*; *Cycloconium* species, such as, for example, *Cycloconium oleaginum*; *Diaporthe* species, such as, for example, *Diaporthe citri*; *Elsinoe* species, such as, for example, *Elsinoe fawcettii*; *Gloeosporium* species, such as, for example, *Gloeosporium laticolor*; *Glomerella* species, such as, for example, *Glomerella cingulata*; *Guignardia* species, such as, for example, *Guignardia bidwelli*; *Leptosphaeria* species, such as, for example, *Leptosphaeria maculans*; *Magnaporthe* species, such as, for example, *Magnaporthe grisea*; *Microdochium* species, such as, for example, *Microdochium nivale*; *Mycosphaerella* species, such as, for example, *Mycosphaerella graminicola* and *M. fijiensis*; *Phaeosphaeria* species, such as, for example, *Phaeosphaeria nodorum*; *Pyrenophora* species, such as, for example, *Pyrenophora teres*; *Ramularia* species, such as, for example, *Ramularia collo-cygni*; *Rhynchosporium* species, such as, for example, *Rhynchosporium secalis*; *Septoria* species, such as, for example, *Septoria apii*; *Typhula* species, such as, for example, *Typhula incarnata*; *Venturia* species, such as, for example, *Venturia inaequalis*;

Root and stem diseases caused, for example, by *Corticium* species, such as, for example, *Corticium graminearum*; *Fusarium* species, such as, for example, *Fusarium oxysporum*; *Gaeumannomyces* species, such as, for example, *Gaeumannomyces graminis*; *Rhizoctonia* species, such as, for example *Rhizoctonia solani*; *Tapesia* species, such as, for example, *Tapesia acuformis*; *Thielaviopsis* species, such as, for example, *Thielaviopsis basicola*;

Ear and panicle diseases (including maize cobs) caused, for example, by *Alternaria* species, such as, for example, *Alternaria* spp.; *Aspergillus* species, such as, for example, *Aspergillus flavus*; *Cladosporium* species, such as, for example, *Cladosporium cladosporioides*; *Claviceps* species, such as, for example, *Claviceps purpurea*; *Fusarium* species, such as, for example, *Fusarium culmorum*;
5 *Gibberella* species, such as, for example, *Gibberella zeae*; *Monographella* species, such as, for example, *Monographella nivalis*; *Septoria* species, such as for example, *Septoria nodorum*;

Diseases caused by smut fungi, such as, for example, *Sphacelotheca* species, such as, for example, *Sphacelotheca reiliana*; *Tilletia* species, such as, for example, *Tilletia caries*; *T. controversa*; *Urocystis* species, such as, for example, *Urocystis occulta*; *Ustilago* species, such as, for example, *Ustilago nuda*; *U. nuda*
10 *tritici*;

Fruit rot caused, for example, by *Aspergillus* species, such as, for example, *Aspergillus flavus*; *Botrytis* species, such as, for example, *Botrytis cinerea*; *Penicillium* species, such as, for example, *Penicillium expansum* and *P. purpurogenum*; *Sclerotinia* species, such as, for example, *Sclerotinia sclerotiorum*; *Verticillium* species, such as, for example, *Verticillium alboatrum*;

15 Seed- and soil-borne rot and wilt diseases, and also diseases of seedlings, caused, for example, by *Fusarium* species, such as, for example, *Fusarium culmorum*; *Phytophthora* species, such as, for example, *Phytophthora cactorum*; *Pythium* species, such as, for example, *Pythium ultimum*; *Rhizoctonia* species, such as, for example, *Rhizoctonia solani*; *Sclerotium* species, such as, for example, *Sclerotium rolfsii*;

20 Cancerous diseases, galls and witches' broom caused, for example, by *Nectria* species, such as, for example, *Nectria galligena*;

Wilt diseases caused, for example, by *Monilinia* species, such as, for example, *Monilinia laxa*;

Deformations of leaves, flowers and fruits caused, for example, by *Taphrina* species, such as, for example, *Taphrina deformans*;

25 Degenerative diseases of woody plants caused, for example, by *Esca* species, such as, for example, *Phaemoniella clamydospora* and *Phaeoacremonium aleophilum* and *Fomitiporia mediterranea*;

Diseases of flowers and seeds caused, for example, by *Botrytis* species, such as, for example, *Botrytis cinerea*;

Diseases of plant tubers caused, for example, by *Rhizoctonia* species, such as, for example, *Rhizoctonia solani*; *Helminthosporium* species, such as, for example, *Helminthosporium solani*;

Diseases caused by bacteriopathogens, such as, for example, *Xanthomonas* species, such as, for example, *Xanthomonas campestris* pv. *oryzae*; *Pseudomonas* species, such as, for example, *Pseudomonas syringae* pv. *lachrymans*; *Erwinia* species, such as, for example, *Erwinia amylovora*.

Preference is given to controlling the following diseases of soya beans:

Fungal diseases on leaves, stems, pods and seeds caused, for example, by alternaria leaf spot (*Alternaria spec. atrans tenuissima*), anthracnose (*Colletotrichum gloeosporoides dematium* var. *truncatum*), brown spot (*Septoria glycines*), cercospora leaf spot and blight (*Cercospora kikuchii*), choanephora leaf blight (*Choanephora infundibulifera trisporea* (Syn.)), dactuliophora leaf spot (*Dactuliophora glycines*), downy mildew (*Peronospora manshurica*), drechslera blight (*Drechslera glycini*), frog-eye leaf spot (*Cercospora sojae*), leptosphaerulina leaf spot (*Leptosphaerulina trifolii*), phyllosticta leaf spot (*Phyllosticta sojaecola*), pod and stem blight (*Phomopsis sojae*), powdery mildew (*Microsphaera diffusa*), pyrenochaeta leaf spot (*Pyrenochaeta glycines*), rhizoctonia aerial, foliage, and web blight (*Rhizoctonia solani*), rust (*Phakopsora pachyrhizi* *Phakopsora meibomia*), scab (*Sphaceloma glycines*), stemphylium leaf blight (*Stemphylium botryosum*), target spot (*Corynespora cassicola*).

Fungal diseases on roots and the stem base caused, for example, by black root rot (*Calonectria crotalariae*), charcoal rot (*Macrophomina phaseolina*), fusarium blight or wilt, root rot, and pod and collar rot (*Fusarium oxysporum*, *Fusarium orthoceras*, *Fusarium semitectum*, *Fusarium equiseti*), mycoleptodiscus root rot (*Mycoleptodiscus terrestris*), neocosmosporea (*Neocosmosporea vasinfecta*), pod and stem blight (*Diaporthe phaseolorum*), stem canker (*Diaporthe phaseolorum* var. *caulivora*), phytophthora rot (*Phytophthora megasperma*), brown stem rot (*Phialophora gregata*), pythium rot (*Pythium aphanidermatum*, *Pythium irregulare*, *Pythium debaryanum*, *Pythium myriotylum*, *Pythium ultimum*), rhizoctonia root rot, stem decay, and damping-off (*Rhizoctonia solani*), sclerotinia stem decay (*Sclerotinia sclerotiorum*), sclerotinia Southern blight (*Sclerotinia rolfsii*), thielaviopsis root rot (*Thielaviopsis basicola*).

It is also possible to control resistant strains of the organisms mentioned above.

Microorganisms capable of degrading or changing the industrial materials which may be mentioned are, for example, bacteria, fungi, yeasts, algae and slime organisms. The active compounds according to the invention preferably act against fungi, in particular moulds, wood-discolouring and wood-

destroying fungi (Basidiomycetes) and against slime organisms and algae. Microorganisms of the following genera may be mentioned as examples: *Alternaria*, such as *Alternaria tenuis*, *Aspergillus*, such as *Aspergillus niger*, *Chaetomium*, such as *Chaetomium globosum*, *Coniophora*, such as *Coniophora puetana*, *Lentinus*, such as *Lentinus tigrinus*, *Penicillium*, such as *Penicillium glaucum*,
5 *Polyporus*, such as *Polyporus versicolor*, *Aureobasidium*, such as *Aureobasidium pullulans*, *Sclerophoma*, such as *Sclerophoma pityophila*, *Trichoderma*, such as *Trichoderma viride*, *Escherichia*, such as *Escherichia coli*, *Pseudomonas*, such as *Pseudomonas aeruginosa*, and *Staphylococcus*, such as *Staphylococcus aureus*.

In addition, the compounds of the formula (I) according to the invention also have very good antimy-
10 cotic activity. They have a very broad antimycotic activity spectrum in particular against dermatophytes and yeasts, moulds and diphaseic fungi (for example against *Candida* species such as *Candida albicans*, *Candida glabrata*) and *Epidermophyton floccosum*, *Aspergillus* species such as *Aspergillus niger* and *Aspergillus fumigatus*, *Trichophyton* species such as *Trichophyton mentagrophytes*, *Microsporon* species such as *Microsporon canis* and *audouinii*. The list of these fungi by no means lim-
15 its the mycotic spectrum which can be covered, but is only for illustration.

When applying the compounds according to the invention the application rates can be varied within a broad range. The dose of active compound/application rate usually applied in the method of treatment according to the invention is generally and advantageously

- for treatment of part of plants, e.g. leaves (foliar treatment): from 0.1 to 10,000 g/ha, preferably
20 bly from 10 to 1,000 g/ha, more preferably from 50 to 300g/ha; in case of drench or drip application, the dose can even be reduced, especially while using inert substrates like rock-wool or perlite;
- for seed treatment: from 2 to 200 g per 100 kg of seed, preferably from 3 to 150 g per 100 kg of seed, more preferably from 2.5 to 25 g per 100 kg of seed, even more preferably from
25 2.5 to 12.5 g per 100 kg of seed;
- for soil treatment: from 0.1 to 10,000 g/ha, preferably from 1 to 5,000 g/ha.

The doses herein indicated are given as illustrative examples of the method according to the invention. A person skilled in the art will know how to adapt the application doses, notably according to the nature of the plant or crop to be treated.

The combination according to the invention can be used in order to protect plants within a certain time range after the treatment against pests and/or phytopathogenic fungi and/or microorganisms. The time range, in which protection is effected, spans in general 1 to 28 days, preferably 1 to 14 days, more preferably 1 to 10 days, even more preferably 1 to 7 days after the treatment of the plants with the combinations or up to 200 days after the treatment of plant propagation material.

Furthermore combinations and compositions according to the invention may also be used to reduce the contents of mycotoxins in plants and the harvested plant material and therefore in foods and animal feed stuff made therefrom. Especially but not exclusively the following mycotoxins can be specified: Deoxynivalenole (DON), Nivalenole, 15-Ac-DON, 3-Ac-DON, T2- und HT2- Toxins, Fumonisin, Zearalenone Moniliformine, Fusarin, Diacetoxyscirpenole (DAS), Beauvericin, Enniatin, Fusaroproliferin, Fusarenol, Ochratoxins, Patulin, Ergosterol and Aflatoxins, which are caused for example by the following fungal diseases: *Fusarium spec.*, like *Fusarium acuminatum*, *F. avenaceum*, *F. crookwellense*, *F. culmorum*, *F. graminearum* (*Gibberella zeae*), *F. equiseti*, *F. fujikuroi*, *F. musarum*, *F. oxysporum*, *F. proliferatum*, *F. poae*, *F. pseudograminearum*, *F. sambucinum*, *F. scirpi*, *F. semitectum*, *F. solani*, *F. sporotrichoides*, *F. langsethiae*, *F. subglutinans*, *F. tricinctum*, *F. verticillioides* and others but also by *Aspergillus spec.*, *Penicillium spec.*, *Claviceps purpurea*, *Stachybotrys spec.* and others.

The good fungicidal activity of the active compound combinations according to the invention is evident from the example below. While the individual active compounds exhibit weaknesses with regard to the fungicidal activity, the combinations have an activity which exceeds a simple addition of activities.

A synergistic effect of fungicides is always present when the fungicidal activity of the active compound combinations exceeds the total of the activities of the active compounds when applied individually.

The expected activity for a given combination of two active compounds can be calculated as follows (cf. Colby, S.R., "Calculating Synergistic and Antagonistic Responses of Herbicide Combinations", *Weeds* **1967**, 15, 20-22):

If

X is the efficacy when active compound A is applied at an application rate of m ppm (or g/ha),

Y is the efficacy when active compound B is applied at an application rate of n ppm (or g/ha),

E is the efficacy when the active compounds A and B are applied at application rates of m and n ppm (or g/ha), respectively, and

$$\text{then } E = X + Y - \frac{X \cdot Y}{100}$$

The degree of efficacy, expressed in % is denoted. 0 % means an efficacy which corresponds to that of the control while an efficacy of 100 % means that no disease is observed.

If the actual fungicidal activity exceeds the calculated value, then the activity of the combination is super-additive, i.e. a synergistic effect exists. In this case, the efficacy which was actually observed must be greater than the value for the expected efficacy (E) calculated from the abovementioned formula.

A further way of demonstrating a synergistic effect is the method of Tammes (cf. "Isoboles, a graphic representation of synergism in pesticides" in *Neth. J. Plant Path.*, **1964**, 70, 73-80).

The invention is illustrated by the examples below. However, the invention is not limited to the examples.

Example

15 **Phytophthora test (tomatoes) / preventive**

Solvent: 24,5 parts by weight of acetone

24,5 parts by weight of dimethylacetamide

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of *Phytophthora infestans*. The plants are then placed in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of 100%.

- 50 -

The test is evaluated 3 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table

Phytophthora test (tomatoes) / protective

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-([3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl)piperidin-4-yl)-1,3-thiazole-4-carboxylate	0,2	52	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-([3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl)piperidin-4-yl)-1,3-thiazole-4-carboxylate	0,4	61	
(3.6)	famoxadone	0,4	0	
(3.7)	fenamidone	0,2	0	
(15.96)	but-3-yn-1-yl {6-[(Z)-((1-methyl-1H-tetrazol-5-yl)-(phenyl)methylene)amino]oxy)methyl}pyridin-2-yl} carbamate	0,2	53	
(I-16) + (3.6)	1:1	0,4 + 0,4	71	61
(I-8) + (3.7)	1:1	0,2 + 0,2	72	52
(I-8) + (15.96)	1:1	0,2 + 0,2	88	77

* found = activity found

** calc. = activity calculated using Colby's formula

Table

Phytophthora test (tomatoes) / protective

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-([3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl)piperidin-4-yl)-1,3-thiazole-4-carboxylate	0,1	26	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-([3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl)piperidin-4-yl)-1,3-thiazole-4-carboxylate	0,4 0,2	74 70	
(15.1)	ametoctradin	0,5	0	
(15.7)	cymoxanil	1	0	
(14.2)	fluazinam	0,5	0	
(15.20)	fosetyl-Al	10	3	
(15.62)	phosphorous acid	10	19	
(10.11)	propamocarb-HCl	10	0	
(I-8) + (15.1)	1:5	0,1 + 0,5	76	26
(I-16) + (15.1)	1:5	0,2 + 1	80	70
(I-8) + (15.7)	1:10	0,1 + 1	48	26
(I-8) + (14.2)	1:5	0,1 + 0,5	61	26
(I-16) + (14.2)	1:5	0,4 + 2	90	74
(I-8) + (15.20)	1:100	0,1 + 10	63	28
(I-16) + (15.20)	1:100	0,4 + 40	90	79
(I-8) + (15.62)	1:100	0,1 + 10	62	40
(I-16) + (15.62)	1:100	0,4 + 40	88	75
(I-8) + (10.11)	1:100	0,1 + 10	73	26

* found = activity found

** calc. = activity calculated using Colby's formula

Example**Plasmopara test (grapevines) / preventive**

Solvent: 24,5 parts by weight of acetone

24,5 parts by weight of dimethylacetamide

5 Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

10 To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of *Plasmopara viticola* and then remain for 1 day in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of 100 %. The plant is subsequently placed for 4 days in a greenhouse at approximately 21°C and a relative atmospheric humidity of approximately 90 %. The plants are then misted and placed for 1 day in an incubation cabinet.

15 The test is evaluated 6 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table

Plasmopara test (grapevines) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	0,4	43	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	0,2	29	
(15.17)	fluopicolide	0,4	43	
(9.5)	mandipropamid	0,2	25	
		0,1	14	
(15.96)	but-3-yn-1-yl {6-[(Z)-{(1-methyl-1H-tetrazol-5-yl)-(phenyl)methylene]amino}oxy)methyl}pyridin-2-yl} carbamate	0,4	46	
(I-8) + (15.17)	1:1	0,4 + 0,4	86	68
(I-8) + (9.5)	1:0,5	0,4 + 0,4	75	57
(I-16) + (9.5)	1:0,5	0,2 + 0,2	52	39
(I-8) + (15.96)	1:1	0,4 + 0,4	89	69

* found = activity found

** calc. = activity calculated using Colby's formula

Table

Plasmopara test (grapevines) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	0,4 0,2	33 40	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	0,4	0	
(12.2)	benalaxyl-m	0,4 0,2	0 0	
(3.3)	cyazofamid	0,4	0	
(9.2)	dimethomorph	0,2	0	
(9.4)	iprovalicarb	0,4	0	
(12.10)	mefenoxam	0,4	57	
(4.9)	zoxamide	0,4	0	
(I-8) + (12.2)	1:1	0,2 + 0,2	52	40
(I-16) + (12.2)	1:1	0,4 + 0,4	62	0
(I-8) + (3.3)	1:1	0,4 + 0,4	72	33
(I-8) + (9.2)	1:1	0,2 + 0,2	53	40
(I-16) + (9.4)	1:1	0,4 + 0,4	33	0
(I-8) + (12.10)	1:1	0,4 + 0,4	93	71
(I-16) + (12.10)	1:1	0,4 + 0,4	70	57
(I-8) + (4.9)	1:1	0,4 + 0,4	57	33

* found = activity found

** calc. = activity calculated using Colby's formula

Example**Venturia test (apples) / preventive**

Solvent: 24,5 parts by weight of acetone

24,5 parts by weight of dimethylacetamide

5 Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

10 To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous conidia suspension of the causal agent of apple scab (*Venturia inaequalis*) and then remain for 1 day in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of 100 %.

15 The plants are then placed in a greenhouse at approximately 21°C and a relative atmospheric humidity of approximately 90 %.

The test is evaluated 10 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table

Venturia test (apples) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	200 100 50	15 0 0	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	200 100 50	33 0 0	
(2.2)	bixafen	1	64	
(5.4)	chlorothalonil	25	83	
(5.16)	copper hydroxide	25	57	
(5.15)	copper oxychloride	50	40	
(2.10)	isopyrazam	1	49	
(5.19)	mancozeb	12,5	53	
(2.20)	penthiopyrad	2	41	
(2.21)	sedaxane	2	69	
(I-8) + (2.2)	50:1	50 + 1	95	64
(I-16) + (2.2)	50:1	50 + 1	83	64
(I-16) + (5.4)	4:1	100 + 25	93	83
(I-16) + (5.16)	4:1	100 + 25	76	57
(I-8) + ((5.15)	4:1	200 + 50	75	49
(I-16) + ((5.15)	4:1	200 + 50	92	60
(I-8) + (2.10)	50:1	50 + 1	80	49
(I-16) + (5.19)	4:1	50 + 12,5	81	53
(I-8) + (2.20)	50:1	100 + 2	61	41
(I-16) + (2.20)	50:1	100 + 2	92	41
(I-8) + (2.21)	50:1	100 + 2	89	69

* found = activity found

** calc. = activity calculated using Colby's formula

Table

Venturia test (apples) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	100 25	27 0	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	100 50	61 15	
(2.6)	fluopyram	2	28	
(2.19)	penflufen	4	0	
(3.8)	fluoxastrobin	0,5	88	
(I-16) + (2.6)	25:1	50 + 2	73	39
(I-8) + (2.19)	25:1	100 + 4	58	27
(I-16) + (2.19)	25:1	100 + 4	92	61
(I-8) + (3.8)	50:1	25 + 0,5	99	88

* found = activity found

** calc. = activity calculated using Colby's formula

Table**Venturia test (apples) / preventive**

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	100	4	
(1.47)	tebuconazole	4	43	
(I-16) + (1.47) 25:1		100 + 4	55	45

* found = activity found

** calc. = activity calculated using Colby's formula

Example**Alternaria test (tomatoes) / preventive**

Solvent: 24,5 parts by weight of acetone

24,5 parts by weight of dimethylacetamide

5 Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

10 To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of *Alternaria solani*. The plants are then placed in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of 100 %.

The test is evaluated 3 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control while an efficacy of 100% means that no disease is observed.

15 The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table

Alternaria test (tomatoes) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	200	0	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	200 50	47 18	
(5.4)	chlorothalonil	50	24	
(5.16)	copper hydroxide	50	47	
(5.15)	copper oxychloride	50	41	
(5.19)	mancozeb	50 12,5	76 18	
(5.23)	propineb	50	53	
(I-16) + (5.4)	4:1	200 + 50	76	60
(I-16) + (5.16)	4:1	200 + 50	87	72
(I-8) + (5.15)	4:1	200 + 50	82	41
(I-8) + (5.19)	4:1	200 + 50	91	76
(I-16) + (5.19)	4:1	50 + 12,5	53	33
(I-8) + (5.23)	4:1	200 + 50	68	53

* found = activity found

** calc. = activity calculated using Colby's formula

Table

Alternaria test (tomatoes) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-([3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl)piperidin-4-yl)-1,3-thiazole-4-carboxylate	100 25	15 0	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-([3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl)piperidin-4-yl)-1,3-thiazole-4-carboxylate	50 25	38 30	
(3.2)	azoxystrobin	0,25	50	
(2.6)	fluopyram	1	55	
(3.8)	fluoxastrobin	2	70	
(2.10)	isopyrazam	0,5	50	
(2.19)	penflufen	1	30	
(2.20)	penthiopyrad	0,5	53	
(2.21)	sedaxane	1	40	
(3.17)	trifloxystrobin	2	60	
(I-8) + (3.2)	100:1	25 + 0,25	60	50
(I-8) + (2.6)	25:1	25 + 1	70	55
(I-8) + (3.8)	50:1	100 + 2	91	75
(I-16) + (2.10)	50:1	25 + 0,5	79	65
(I-8) + (2.19)	25:1	25 + 1	50	30
(I-16) + (2.20)	50:1	25 + 0,5	83	67
(I-16) + (2.21)	50:1	50 + 1	73	63
(I-8) + (3.17)	50:1	100 + 2	93	66

* found = activity found

** calc. = activity calculated using Colby's formula

Example**Sphaerotheca test (cucumbers) / preventive**

Solvent: 24,5 parts by weight of acetone

24,5 parts by weight of dimethylacetamide

5 Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

10 To test for protect activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of *Sphaerotheca fuliginea*. The plants are then placed in a greenhouse at approximately 23°C and a relative atmospheric humidity of approximately 70 %.

The test is evaluated 7 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

15 The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table**Sphaerotheca test (cucumbers) / preventive**

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	100	0	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	100	0	
(2.45)	fluxapyroxad	2	30	
(I-8) + (2.45)	50:1	100 + 2	73	30
(I-16) + (2.45)	50:1	100 + 2	63	30

* found = activity found

** calc. = activity calculated using Colby's formula

Table

Sphaerotheca test (cucumbers) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	100	30	
		50	30	
		25	0	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	100	43	
		50	30	
		25	30	
(1.19)	fluquinconazole	1	78	
(1.40)	propiconazole	2	78	
(1.41)	prothioconazole	0,5	37	
(1.47)	tebuconazole	4	67	
(I-8) + (1.19)	50:1	50 + 1	95	85
(I-16) + (1.19)	50:1	50 + 1	95	85
(I-8) + (1.40)	50:1	100 + 2	95	85
(I-8) + (1.41)	50:1	25 + 0,5	57	37
(I-16) + (1.41)	50:1	25 + 0,5	82	56
(I-8) + (1.47)	25:1	100 + 4	95	77
(I-16) + (1.47)	25:1	100 + 4	95	81

* found = activity found

** calc. = activity calculated using Colby's formula

Table

Sphaerotheca test (cucumbers) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	100	20	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	100	37	
(3.2)	azoxystrobin	1	10	
(2.6)	fluopyram	4	0	
(2.19)	penflufen	4	0	
(3.13)	pyraclostrobin	1	0	
(3.17)	trifloxystrobin	2	27	
(I-8) + (3.2)	100:1	100 + 1	50	28
(I-8) + (2.6)	25:1	100 + 4	50	20
(I-8) + (2.19)	25:1	100 + 4	80	20
(I-16) + (2.19)	25:1	100 + 4	50	37
(I-8) + (3.13)	100:1	100 + 1	50	20
(I-8) + (3.17)	50:1	100 + 2	93	42
(I-16) + (3.17)	50:1	100 + 2	80	54

* found = activity found

** calc. = activity calculated using Colby's formula

Example**Botrytis test (beans) / preventive**

Solvent: 24,5 parts by weight of acetone

24,5 parts by weight of dimethylacetamide

5 Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound.

10 After the spray coating has dried on, 2 small pieces of agar covered with growth of *Botrytis cinerea* are placed on each leaf. The inoculated plants are placed in a darkened chamber at 20°C and a relative atmospheric humidity of 100%.

2 days after the inoculation, the size of the lesions on the leaves is evaluated. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease

15 is observed.

The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table**Botrytis test (beans) / preventive**

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	(1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	200 50	0 0	
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	200 50	0 0	
(1.16)	fenhexamid	10	0	
(13.2)	fludioxonil	10	15	
(5.9)	folpet	12,5	11	
(7.7)	pyrimethanil	50	11	
(I-16) + (1.16)	20:1	200 + 10	50	0
(I-8) + (13.2)	20:1	200 + 10	75	15
(I-16) + (13.2)	20:1	200 + 10	73	15
(I-8) + (5.9)	4:1	50 + 12,5	63	11
(I-18) + (5.9)	4:1	50 + 12,5	58	11
(I-8) + (7.7)	4:1	200 + 50	51	11
(I-16) + (7.7)	4:1	200 + 50	59	11

* found = activity found

** calc. = activity calculated using Colby's formula

Example**Blumeria test (barley) / preventive**

Solvent: 49 parts by weight of n,n-dimethylacetamid

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

- 5 To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.

- 10 After the spray coating has been dried, the plants are dusted with spores of *Blumeria graminis f.sp. hordei*.

The plants are placed in the greenhouse at a temperature of approximately 18°C and a relative atmospheric humidity of approximately 80% to promote the development of mildew pustules.

- 15 The test is evaluated 7 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table**Blumeria test (barley) / preventive**

Active compounds	Application rate of active compound in ppm a.i.	Efficacy in %	
		found*	calc.**
(I-8) (1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	1000	33	
(2.19) penflufen	125	67	
(I-8) + (2.19) 8:1	1000 + 125	100	78

* found = activity found

** calc. = activity calculated using Colby's formula

Table5 **Blumeria test (barley) / preventive**

Active compounds	Application rate of active compound in ppm a.i.	Efficacy in %	
		found*	calc.**
(I-16) 2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	1000	0	
(1.46) spiroxamine	250	94	
(2.19) penflufen	125	56	
(I-16) + (1.46) 4:1	1000 + 250	100	94
(I-16) + (2.19) 8:1	1000 + 125	94	56

* found = activity found

** calc. = activity calculated using Colby's formula

Example**Leptosphaeria nodorum test (wheat) / preventive**

Solvent: 49 parts by weight of n,n-dimethylacetamid

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

- 5 To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.

- 10 After the spray coating has been dried, the plants are sprayed with a spore suspension of *Leptosphaeria nodorum*. The plants remain for 48 hours in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of approximately 100%.

The plants are placed in the greenhouse at a temperature of approximately 22°C and a relative atmospheric humidity of approximately 80%.

- 15 The test is evaluated 8 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table**Leptosphaeria nodorum test (wheat) / preventive**

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	1000	0	
(1.51)	triadimenol	250	50	
(3.2)	azoxystrobin	31,25	67	
(I-8) + (1.51)	4:1	1000 + 250	83	50
(I-8) + (3.2)	32:1	1000 + 31,25	92	67

* found = activity found

** calc. = activity calculated using Colby's formula

Table5 **Leptosphaeria nodorum test (wheat) / preventive**

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	1000	14	
(13.1)	fenpiclonil	500	71	
(13.2)	fludioxonil	250	43	
(3.13)	pyraclostrobin	31,25	57	
(I-8) + (13.1)	2:1	1000 + 500	93	75
(I-8) + (13.2)	4:1	1000 + 250	100	51
(I-8) + (3.13)	32:1	1000 + 31,25	100	63

* found = activity found

** calc. = activity calculated using Colby's formula

Table

Leptosphaeria nodorum test (wheat) / preventive

Active compounds	Application rate of active compound in ppm a.i.	Efficacy in %	
		found*	calc.**
(I-16) 2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	1000	0	
(1.12) epoxiconazole	31,25	71	
(1.19) fluquinconazole	31,25	43	
(1.41) prothioconazole	62,5	43	
(1.51) triadimenol	250	43	
(3.2) azoxystrobin	62,5	86	
(3.8) fluoxastrobin	31,25	71	
(I-16) + (1.12) 32:1	1000 + 31,25	86	71
(I-16) + (1.19) 32:1	1000 + 31,25	93	43
(I-16) + (1.41) 16:1	1000 + 62,5	93	43
(I-16) + (1.51) 4:1	1000 + 250	86	43
(I-16) + (3.2) 16:1	1000 + 62,5	100	86
(I-16) + (3.8) 32:1	1000 + 31,25	86	71

* found = activity found

** calc. = activity calculated using Colby's formula

Example**Pyrenophora teres-test (barley) / preventive**

Solvent: 49 parts by weight of n,n-dimethylacetamid

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

- 5 To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.

- 10 After the spray coating has been dried, the plants are sprayed with a spore suspension of ***Pyrenophora teres***. The plants remain for 48 hours in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of approximately 100%.

The plants are placed in the greenhouse at a temperature of approximately 20°C and a relative atmospheric humidity of approximately 80%.

- 15 The test is evaluated 8 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

- 75 -

Table**Pyrenophora teres-test (barley) / preventive**

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	1000	13	
		500	0	
(2.6)	fluopyram	31,25	88	
(3.17)	trifloxystrobin	62,5	75	
(13.1)	fenpiclonil	500	88	
(13.2)	fludioxonil	125	88	
(I-16) + (2.6)	32:1	1000 + 31,25	100	90
(I-16) + (3.17)	16:1	1000 + 62,5	100	78
(I-16) + (13.1)	1:1	500 + 500	100	88
(I-16) + (13.2)	8:1	1000 + 125	100	90

* found = activity found

** calc. = activity calculated using Colby's formula

Pyrenophora teres-test (barley) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-16)	2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	1000	25	
(1.47)	tebuconazole	125	38	
(I-16) + (1.47)	32:1	1000 + 125	88	54

* found = activity found

** calc. = activity calculated using Colby's formula

PAGE INTENTIONALLY LEFT BLANK

Example**Puccinia triticina-test (wheat) / preventive**

Solvent: 49 parts by weight of n,n-dimethylacetamid

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

- 5 To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.

- 10 After the spray coating has been dried, the plants are sprayed with a spore suspension of *Puccinia triticina*. The plants remain for 48 hours in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of approximately 100%.

The plants are placed in the greenhouse at a temperature of approximately 20°C and a relative atmospheric humidity of approximately 80%.

- 15 The test is evaluated 8 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table

Puccinia triticina-test (wheat) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	2-chloro-6-fluorobenzyl 2-(1-{{3,5-bis(difluoromethyl)-1H-pyrazol-1-yl}acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	1000	0	
		500	0	
(1.40)	propiconazole	125	78	
(1.46)	spiroxamine	500	56	
(2.3)	boscalid	500	56	
(3.17)	trifloxystrobin	62,5	78	
(I-8) + (1.40)	4:1	500 + 125	100	78
(I-8) + (1.46)	1:1	500 + 500	78	56
(I-8) + (2.3)	2:1	1000 + 500	100	56
(I-8) + (3.17)	16:1	1000 + 62,5	100	78

* found = activity found

** calc. = activity calculated using Colby's formula

Table

Puccinia triticina-test (wheat) / preventive

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-16) 2-chloro-6-fluorobenzyl 2-(1-{{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate		1000	38	
		500	13	
(2.3) boscalid		250	38	
(3.13) pyraclostrobin		62,5	63	
(I-16) + (2.3) 2:1		500 + 250	88	46
(I-16) + (3.13) 16:1		1000 + 62,5	100	77

* found = activity found

** calc. = activity calculated using Colby's formula

Example**Septoria tritici-test (wheat) / preventive**

Solvent: 49 parts by weight of n,n-dimethylacetamid

Emulsifier: 1 part by weight of alkylaryl polyglycol ether

- 5 To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.

- 10 After the spray coating has been dried, the plants are sprayed with a spore suspension of *Septoria tritici*. The plants remain for 48 hours in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of approximately 100% and afterwards for 60 hours at approximately 15°C in a translucent incubation cabinet at a relative atmospheric humidity of approximately 100%.

- 15 The plants are placed in the greenhouse at a temperature of approximately 15°C and a relative atmospheric humidity of approximately 80%.

The test is evaluated 21 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.

Table**Septoria tritici-test (wheat) / preventive**

Active compounds		Application rate of active compound in ppm a.i.	Efficacy in %	
			found*	calc.**
(I-8)	2-chloro-6-fluorobenzyl 2-(1-{{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate	1000	0	
		500	0	
(1.12)	epoxiconazole	62,5	71	
(1.19)	fluquinconazole	62,5	86	
(1.41)	prothioconazole	125	86	
(2.6)	fluopyram	31,25	80	
(3.8)	fluoxastrobin	62,5	71	
(I-8) + (1.12)	16:1	1000 + 62,5	100	71
(I-8) + (1.19)	16:1	1000 + 62,5	100	86
(I-8) + (1.41)	4:1	500 + 125	100	86
(I-8) + (2.6)	16:1	500 + 31,25	100	80
(I-8) + (3.8)	16:1	1000 + 62,5	100	71


* found = activity found

** calc. = activity calculated using Colby's formula

Patent Claims

1. Active compound combinations comprising

(A) at least one thiazol-4-carbonic acid ester of formula (I)



5 in which


R^1 represents CF_3 or CHF_2

R^2 represents methyl or CHF_2

R^3 represents cyclohexyl, (1S/1R)-1,2,3,4-tetrahydronaphthalen-1-yl, (1S)-1,2,3,4-tetrahydronaphthalen-1-yl, (1R)-1,2,3,4-tetrahydronaphthalen-1-yl or 1-naphthyl,

10 or

R^3 represents



R^4 represents hydrogen, fluoro, chloro, bromo or iodo

R^5 represents hydrogen, fluoro, chloro, bromo, iodo or phenyl

15 or an agrochemically acceptable salt thereof,

and

(B) at least one further active compound selected from the following groups

(1) inhibitors of the ergosterol synthesis,

(2) inhibitors of the respiratory chain at complex I or II,

- (3) inhibitors of the respiratory chain at complex III,
 - (4) inhibitors of the mitosis and cell division,
 - (5) compounds capable of having a multisite action,
 - (6) compounds capable of inducing a host defense,
 - 5 (7) inhibitors of the amino acid and/or protein biosynthesis,
 - (8) inhibitors of the ATP production,
 - (9) inhibitors of the cell wall synthesis,
 - (10) inhibitors of the lipid and membrane synthesis,
 - (11) inhibitors of the melanine biosynthesis,
 - 10 (12) inhibitors of the nucleic acid synthesis,
 - (13) inhibitors of the signal transduction,
 - (14) compounds capable of acting as uncoupler,
 - (15) other fungicides.
2. Active compound combinations according to Claim 1, wherein the compound of the formula
- 15 (I) is (I-1) cyclohexyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-2) cyclohexyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-3) (1S/1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-4) (1S/1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-5) (1S)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-6) (1S)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-7) (1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-8) (1R)-1,2,3,4-tetrahydronaphthalen-1-yl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl} piperidin-
- 20
- 25

- 4-yl)-1,3-thiazole-4-carboxylate, (I-9) 1-naphthyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-10) 1-naphthyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-11) 2-bromobenzyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-12) 2-bromobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-13) 2,6-difluorobenzyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-14) 2,6-difluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate, (I-15) 2-chloro-6-fluorobenzyl 2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate or (I-16) 2-chloro-6-fluorobenzyl 2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazole-4-carboxylate.
3. Active compound combinations according to Claim 1 oder Claim 2, wherein the further active compound is selected from the group consisting of (1.1) aldimorph, (1.2) azaconazole, (1.3) biter-tanol, (1.4) bromuconazole, (1.5) cyproconazole, (1.6) diclobutrazole, (1.7) difenoconazole, (1.8) diniconazole, (1.9) diniconazole-M, (1.10) dodemorph, (1.11) dodemorph acetate, (1.12) epoxiconazole, (1.13) etaconazole, (1.14) fenarimol, (1.15) fenbuconazole, (1.16) fenhexamid, (1.17) fenpropidin, (1.18) fenpropimorph, (1.19) fluquinconazole, (1.20) flurprimidol, (1.21) flusilazole, (1.22) flutriafol, (1.23) furconazole, (1.24) furconazole-cis, (1.25) hexaconazole, (1.26) imazalil, (1.27) imazalil sulfate, (1.28) imibenconazole, (1.29) ipconazole, (1.30) metconazole, (1.31) myclobutanil, (1.32) naftifine, (1.33) nuarimol, (1.34) oxpoconazole, (1.35) paclobutrazol, (1.36) pefurazoate, (1.37) penconazole, (1.38) piperalin, (1.39) prochloraz, (1.40) propiconazole, (1.41) prothioconazole, (1.42) pyributicarb, (1.43) pyrifenoxy, (1.44) quinconazole, (1.45) simeconazole, (1.46) spiroxamine, (1.47) tebuconazole, (1.48) terbinafine, (1.49) tetraconazole, (1.50) triadimefon, (1.51) triadimenol, (1.52) tridemorph, (1.53) triflumizole, (1.54) triforine, (1.55) triticonazole, (1.56) uniconazole, (1.57) viniconazole, (1.58) 1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)cycloheptanol, (1.59) methyl 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazole-5-carboxylate, (1.60) O-{1-[(4-methoxyphenoxy)methyl]-2,2-dimethylpropyl}-1H-imidazole-1-carbothioate, (1.61) N-ethyl-N-methyl-N'-{2-methyl-5-(difluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}-imidoformamid, (1.62) N-ethyl-N-methyl-N'-{2-methyl-5-(trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}-imidoformamid, (1.63) voriconazole, (1.64) uniconazole-p, (2.1) diflumermorim, (2.2) bixafen, (2.3) boscalid, (2.4) carboxin, (2.5) fenfuram, (2.6) fluopyram, (2.7) flutolanil, (2.8) furametpyr, (2.9) furmecyclox, (2.10) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate

1RS,4SR,9SR), (2.11) isopyrazam (syn epimeric racemate 1RS,4SR,9RS), (2.12) isopyrazam (syn-epimeric enantiomer 1R,4S,9R), (2.13) isopyrazam (syn-epimeric enantiomer 1S,4R,9S), (2.14) isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), (2.15) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.16) isopyrazam (anti-epimeric enantiomer 1S,4R,9R), (2.17) mepronil, (2.18) oxycarboxin, (2.19) penflufen, (2.20) penthiopyrad, (2.21) sedaxane, (2.22) thifluzamide, (2.23) 1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (2.24) 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide, (2.25) 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide, (2.26) 1-methyl-3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2.27) N-(4'-chlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.28) N-(2',4'-dichlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.29) 3-(difluoromethyl)-1-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2.30) N-(2',5'-difluorobiphenyl-2-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (2.31) 3-(difluoromethyl)-1-methyl-N-(4'-prop-1-yn-1-ylbiphenyl-2-yl)-1H-pyrazole-4-carboxamide, (2.32) 5-fluoro-1,3-dimethyl-N-(4'-prop-1-yn-1-ylbiphenyl-2-yl)-1H-pyrazole-4-carboxamide, (2.33) 2-chloro-N-(4'-prop-1-yn-1-ylbiphenyl-2-yl)nicotinamide, (2.34) 3-(difluoromethyl)-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide, (2.35) N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, (2.36) N-[4'-(ethinylbiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.37) N-(4'-ethinylbiphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, (2.38) 2-chloro-N-(4'-ethinylbiphenyl-2-yl)-nicotinamide, (2.39) 2-chloro-N-[4'-(3,3-dimethylbut-1-in-1-yl)biphenyl-2-yl]-nicotinamide, (2.40) 4-(difluoromethyl)-2-methyl-N-[4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]-1,3-thiazole-5-carboxamide, (2.41) 5-fluoro-N-[4'-(3-hydroxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide, (2.42) 2-chloro-N-[4'-(3-hydroxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-nicotinamide, (2.43) 3-difluoromethyl-N-[4'-(3-methoxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide, (2.44) 5-fluoro-N-[4'-(3-methoxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide, (2.45) 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)-1H-pyrazole-4-carboxamide, (2.46) 2-chloro-N-[4'-(3-methoxy-3-methylbut-1-in-1-yl)biphenyl-2-yl]-nicotinamide, (2.47) N-[1-(2,4-dichlorophenyl)-1-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (3.1) amisulbrom, (3.2) azoxystrobin, (3.3) cyazofamid, (3.4) dimoxystrobin, (3.5) enestroburin, (3.6) famoxadone, (3.7) fenamidone, (3.8) fluoxastrobin, (3.9) kresoxim-methyl, (3.10) metominostrobin, (3.11) orysastrobin, (3.12) picoxystrobin, (3.13)

pyraclostrobin, (3.14) pyrametostrobin, (3.15) pyraoxystrobin, (3.16) pyribencarb, (3.17) trifloxystrobin, (3.18) 5-methoxy-2-methyl-4-(2-{{[(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino]oxy}methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, (3.19) (2E)-2-(2-{{[6-(3-chloro-2-methyl-phenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl}-2-(methoxyimino)-N-methylethanamide, (3.20) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-pyridine-3-carboxamide, (3.21) (2E)-2-(methoxyimino)-N-methyl-2-(2-{{[(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino]oxy}methyl}-phenyl)ethanamide, (3.22) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-(formylamino)-2-hydroxy-benzamide, (3.23) (2E)-2-(methoxyimino)-N-methyl-2-{{[(E)-({1-[3-(trifluoromethyl)phenyl]ethoxy}imino)methyl]phenyl}ethanamide, (3.24) (2E)-2-{{[[{(2E,3E)-4-(2,6-dichlorophenyl)but-3-en-2-ylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylethanamide, (3.25) (2E)-2-{{2-[[{(1E)-1-(3-{{[(E)-1-fluoro-2-phenylvinyl]oxy}-phenyl]ethylidene}amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide, (3.26) methyl (2E)-2-{{2-[[{cyclopropyl[(4-methoxyphenyl)imino]methyl}thio)methyl]phenyl}-3-methoxyacrylate, (3.27) 2-{{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (3.28) (2R)-2-{{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (4.1) benomyl, (4.2) carbendazim, (4.3) diethofencarb, (4.4) ethaboxam, (4.5) fuberidazole, (4.6) pencycuron, (4.7) thiabendazole, (4.8) thiophanate-methyl, (4.9) zoxamide, (4.10) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine, (4.11) chlorfenazole, (4.12) thiophanate, (4.13) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine, (5.1) bordeaux mixture, (5.2) captafol, (5.3) captan, (5.4) chorothalonil, (5.5) dichlofluanid, (5.6) dithianon, (5.7) dodine, (5.8) ferbam, (5.9) folpet, (5.10) guazatine, (5.11) iminoctadine, (5.12) iminoctadine triacetate, (5.13) iminoctadine tris(albesilate), (5.14) copper oxide, (5.15) copper oxychlorid, (5.16) copper hydroxide, (5.17) copper sulfate, (5.18) mancopper, (5.19) mancozeb, (5.20) maneb, (5.21) metiram, (5.22) oxine copper, (5.23) propineb, (5.24) sulphur and sulphur preparations including calcium polysulphide, (5.25) thiram, (5.26) tolylfluanid, (5.27) zineb, (5.28) ziram, (5.29) copper naphthenate, (5.30) dodine free base, (5.31) fluorofolpet, (5.32) guazatine acetate, (5.33) metiram zinc, (5.34) propamidine, (6.1) acibenzolar-S-methyl, (6.2) probendazole, (6.3) tiadinil, (7.1) andoprim, (7.2) blasticidin-S, (7.3) cyprodinyl, (7.4) kasugamycin, (7.5) kasugamycin hydrochloride hydrate, (7.6) mepanipyrim, (7.7) pyrimethanil, (8.1) fentin acetate, (8.2) fentin hydroxide, (8.3) silthiofam, (9.1) benthiavalicarb, (9.2) dimethomorph, (9.3) flumorph, (9.4) iprovalicarb, (9.5) mandipropamid, (9.6) polyoxins, (9.7) polyoxorim, (9.8) porthiocarb, (9.9) validamycin A, (9.10) vali fenalate, (9.11) N-[2-(4-{{[3-(4-chlorophenyl)prop-2-yn-1-yl]oxy}-3-methoxyphenyl]ethyl}-N²-(methylsulfonyl)valinamide, (10.1) biphenyl, (10.2) chlozolate, (10.3) edifenfos, (10.4)

etridiazole, (10.5) iodocarb, (10.6) iprobenfos, (10.7) iprodione, (10.8) isoprothiolane, (10.9)
 procymidone, (10.10) propamocarb, (10.11) propamocarb-hydrochloride, (10.12) pyrazophos,
 (10.13) tolcofos-methyl, (10.14) vinclozolin, (11.1) carpropamid, (11.2) diclocymet, (11.3)
 fenoxanil, (11.4) phthalide, (11.5) pyroquilon, (11.6) tricyclazole, (12.1) benalaxyl, (12.2)
 5 benalaxyl-M (kiralaxyl), (12.3) bupirimate, (12.4) clozylacon, (12.5) dimethirimol, (12.6)
 ethirimol, (12.7) furalaxyl, (12.8) hymexazol, (12.9) metalaxyl, (12.10) metalaxyl-M
 (mefenoxam), (12.11) ofurace, (12.12) oxadixyl, (12.13) oxolinic acid, (13.1) fenpiclonil, (13.2)
 fludioxonil, (13.3) quinoxifen, (14.1) dinocap, (14.2) fluazinam, (14.3) meptyldinocap, (14.4)
 binapacryl, (15.1) ametocradin, (15.2) benthiazole, (15.3) bethoxazin, (15.4) carvone, (15.5)
 10 chinomethionat, (15.6) cyflufenamid, (15.7) cymoxanil, (15.8) dazomet, (15.9) debacarb, (15.10)
 dichlorophen, (15.11) diclomezine, (15.12) dicloran, (15.13) difenzoquat, (15.14) diphenylamine,
 (15.15) ferimzone, (15.16) flumetover, (15.17) fluopicolide, (15.18) fluoroimide, (15.19) flusulf-
 amide, (15.20) fosetyl-Al, (15.21) hexachlorobenzene, (15.22) isotianil, (15.23) methasulfocarb,
 (15.24) methylisothiocyanate, (15.25) metrafenone, (15.26) nitrothal-isopropyl, (15.27)
 15 oocthilonone, (15.28) oxyfenthiin, (15.29) propamocarb-fosetilate, (15.30) proquinazid, (15.31)
 pyrrolnitrine, (15.32) quintozone, (15.33) tecloftalam, (15.34) tecnazene, (15.35) triazoxide,
 (15.36) trichlamide, (15.37) zarilamide, (15.38) 8-hydroxyquinoline sulfate, (15.39) 2,3,5,6-
 tetrachloro-4-(methylsulfonyl)pyridine, (15.40) 3,4,5-trichloropyridine-2,6-dicarbonitrile, (15.41)
 3-[5-(4-chlorophenyl)-2,3-dimethylisoxazolidin-3-yl]pyridine, (15.42) N-(4-chloro-2-nitrophenyl)-
 20 N-ethyl-4-methylbenzenesulfonamide, (15.43) 2-butoxy-6-iodo-3-propyl-benzopyran-4-one,
 (15.44) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2,4-dichloronicotinamide, (15.45) N-[(5-
 bromo-3-chloropyridin-2-yl)methyl]-2,4-dichloronicotinamide, (15.46) N-[1-(5-bromo-3-
 chloropyridin-2-yl)ethyl]-2-fluoro-4-iodonicotinamide, (15.47) N-(4-chlorobenzyl)-3-[3-methoxy-
 4-(prop-2-yn-1-yloxy)phenyl]propanamide, (15.48) N-[(4-chlorophenyl)(cyano)methyl]-3-[3-
 25 methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, (15.49) S-allyl-5-amino-2-isopropyl-4-(2-
 methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carboxylic acid, (15.50) 2,3-dibutyl-6-
 chlorothieno[2,3-d]pyrimidin-4(3H)-one, (15.51) ethyl (2Z)-3-amino-2-cyano-3-phenylprop-2-
 enoate, (15.52) 5-amino-1,3,4-thiadiazole-2-thiol, (15.53) 1-[(4-methoxyphenoxy)methyl]-2,2-di-
 methylpropyl 1H-imidazole-1-carboxylate, (15.54) 3-chloro-5-(4-chlorophenyl)-4-(2,6-difluoro-
 30 phenyl)-6-methylpyridazine, (15.55) 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethyl-
 pyridazine, (15.56) tebufloquin, (15.57) flutianil, (15.58) (5-bromo-2-methoxy-4-methylpyridin-
 3-yl)(2,3,4-trimethoxy-6-methylphenyl)methanone, (15.59) tolifenamide, (15.60) N-[(Z)-[(cyclo-
 propylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl]-2-phenylacetamide,
 (15.61) N-[(E)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl]-2-

phenylacetamide, (15.62) phosphorous acid and its salts, (15.63) 5-chloro-N'-phenyl-N'-prop-2-yn-1-ylthiophene-2-sulfonohydrazide, (15.64) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide, (15.65) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-thiazole-4-carboxamide, (15.66) pentyl 6-[[[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylidene]amino]oxy)methyl]pyridin-2-yl} carbamate, (15.67) capsimycin, (15.68) chloroneb, (15.69) cufraneb, (15.70) cyprosulfamide, (15.71) difenzoquat methylsulphate, (15.72) ecomate, (15.73) fosetyl-calcium, (15.74) fosetyl-sodium, (15.75) irumamycin, (15.76) mildiomyacin, (15.77) natamycin, (15.78) nickel dimethyldithiocarbamate, (15.79) oxamocarb, (15.80) pentachlorophenol and salts, (15.81) phenazine-1-carboxylic acid, (15.82) phenothrin, (15.83) propanosine-sodium, (15.84) quinolin-8-ol, (15.85) 2-phenylphenol and salts, (15.86) 5-methyl-6-octyl-3,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, (15.87) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5R)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (15.88) 1-(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (15.89) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide, (15.90) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (15.91) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (15.92) 1-(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (15.93) 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (15.94) chlazafenone, (15.95) 2-chloro-5-[2-chloro-1-(2,6-difluoro-4-methoxyphenyl)-4-methyl-1H-imidazol-5-yl]pyridine, (15.96) but-3-yn-1-yl{6-[[[(Z)-(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino]oxy)methyl]pyridin-2-yl} carbamate.

4. Compositions comprising active compound combinations according to Claim 1 and further comprising auxiliaries, solvents, carriers, surfactants or extenders.
5. Method for controlling phytopathogenic fungi in crop protection, characterized in that active compound combinations according to Claim 1 or compositions according to Claim 2 or 4 are applied to the seed, the plant, to fruits of plants or to the soil on which the plant grows or is supposed to grow.

6. Method according to Claim 5, characterized in that the plant, the fruits of plants or the soil on which the plant grows or is intended to grow are treated.
7. Method according to Claim 5, characterized in that in the treatment of leaves from 0.1 to 10 000 g/ha and in the treatment of seed from 2 to 200 g per 100 kg of seed are employed.
- 5 8. Use of active compound combinations according to Claim 1 or of compositions according to Claim 2 or 4 for controlling unwanted phytopathogenic fungi in crop protection.
9. Use of active compound combinations according to Claim 1 or of compositions according to Claim 2 or 4 for treating seed, seed of transgenic plants and transgenic plants.
10. Seed treated with active compound combinations according to Claim 1 or with compositions
10 according to Claim 2 or 4.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/066096

A. CLASSIFICATION OF SUBJECT MATTER

INV. A01N43/78 A01P3/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2009/132785 A1 (BAYER CROPS SCIENCE AG [DE]; CRISTAU PIERRE [DE]; HERRMANN STEFAN [DE];) 5 November 2009 (2009-11-05) cited in the application claims 1-14 table 1 page 48, last paragraph - page 49, paragraph 1	1,4-10
A	----- WO 2007/014290 A2 (DU PONT [US]; BISAHA JOHN JOSEPH [US]; KOVACS PATRICK RYAN [US]; LETT) 1 February 2007 (2007-02-01) cited in the application claims 1-22 -----	1-10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 March 2011

Date of mailing of the international search report

01/04/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Marie, Gérald

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2010/066096

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
W0 2009132785	A1	05-11-2009	AU 2009243401 A1	05-11-2009
			CA 2722775 A1	05-11-2009
			EP 2280965 A1	09-02-2011
			KR 20100135952 A	27-12-2010

W0 2007014290	A2	01-02-2007	AR 057688 A1	12-12-2007
			AU 2006272551 A1	01-02-2007
			CA 2614288 A1	01-02-2007
			CN 101228156 A	23-07-2008
			EC SP088112 A	20-02-2008
			EP 1948649 A2	30-07-2008
			GT 200600329 A	26-03-2007
			JP 2009502948 T	29-01-2009
			KR 20080031030 A	07-04-2008
			NZ 564017 A	29-01-2010
			PE 03702007 A1	11-05-2007
			UY 29695 A1	28-02-2007
			ZA 200711055 A	26-08-2009
